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Introductory Chapter (Thesis Overview) 
 
This thesis aims to increase clinical understanding of depression and anxiety in people 
living with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), a disabling long-
term condition for which there is currently no known cure. Two clinical papers are presented. 
Each examines potentially relevant psychological mechanisms.  
Due to the lack of effective medical treatments for CFS/ME, clinical focus is presently the 
management of physical symptoms, primarily with a view to reducing levels of fatigue (White et 
al., 2011). At a research level, there has been greater examination of factors associated with 
fatigue, with associated depression and anxiety being under-researched. This is despite the high 
levels of reported co-morbidity (Larkin & Martin, 2017), and evidence for the dynamic interplay 
between mental and physical health (Kiecolt-Glaser et al., 2002)  
The role of psychology in supporting people with CFS/ME is mired in controversy.  
Examination of co-morbid mental health difficulties in CFS/ME has been hampered by 
symptomatic overlap with depression (Griffith & Zarrouf, 2008), methodological concerns 
regarding previous psychological research and treatment (Laws, 2017; Vink & Vink-Niese, 2019) 
and concerns raised by patient activist groups (Kelland, 2019). On the one hand, critics caution of 
the ‘psychologisation of physical illness’ (Gaudsmit & Gadd, 1991; Richman & Jason, 2001); on 
the other, the rejection of psychology as a relevant discipline risks neglecting the research and 
treatment of co-morbid mental health difficulties. Greater understanding of associated 
psychological factors could inform the development of evidence based, CFS/ME specific 
therapeutic interventions, aimed at reducing co-morbid depression and anxiety. Such targeted 
interventions would complement a multi-disciplinary approach to CFS/ME and would not seek to 
refute potentially underlying organic pathology.  
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Potentially predisposing personality traits has been one controversial area of research into 
CFS/ME. Perfectionism has attracted attention (Kempke et al., 2015), driven in part by clinical 
observations (Surawy et al., 1995) and arguably stereotyping (Deary & Chalder, 2008). However, 
this may remain a valid area of research with regards to co-morbid depression and anxiety;  
perfectionism has been found to be a trans-diagnostic risk factor for a range of both physical and 
mental health conditions (Egan, Wade, Shafran, 2011), and higher levels of perfectionism have 
been evidenced in people living with CFS/ME (White & Schweitzer, 2000). It is therefore 
clinically important to consider the potential relationship between perfectionism and emotional 
distress in physical health populations, including CFS/ME. However, research to date has 
focussed on the relationship between perfectionism and fatigue, as well as perfectionism as a 
predisposing risk factor for CFS/ME. Within the CFS/ME population, the association between 
perfectionism and depression and/or anxiety is under-researched, hence the selection of the 
question addressed in Chapter 1: What is the relationship between perfectionism and co-morbid 
depression and anxiety in people living with CFS/ME?  
Chapter 1 systematically reviews the existing evidence of a relationship between 
perfectionism and either depression or anxiety, in this patient group. This process identified 7 
relevant studies reported in 8 papers. Several factors of perfectionism were explored. Consistent 
with the wider literature and psychological theory, narrative synthesis indicated maladaptive 
perfectionism was consistently associated with depression. However, evidence for associations 
with other aspects of perfectionism was inconsistent. The relationship between perfectionism and 
anxiety in CFS/ME was identified as an under-researched area.  
The review was prepared for submission to the Journal of Psychosomatic Research and 
formatted accordingly (see Appendix A). The journal was chosen because of its focus upon the 
relevance of psychological processes in physical health. Findings of the review are intended to 
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guide directions for future research, in addition to therapeutic interventions which seek to reduce 
depression in this patient group.  
Chapter 2 examines the potential applicability of the Self-Regulatory Executive Function 
(S-REF) model of emotional distress (Wells & Matthews 1994) to understanding depression and 
anxiety experienced alongside CFS/ME. This model predicts that prolonged distress arises not 
from symptom-related appraisals or thought content per se, but rather metacognitive beliefs about 
worry and/or rumination, which drive unhelpful thought processes and responses; this is termed 
the cognitive-attentional syndrome (CAS; Wells & Matthews 1994). Two types of metacognitive 
belief are theorised to be of particular importance in activating and maintaining the CAS: positive 
metacognitive beliefs about the usefulness of worry, e.g. ‘Worrying helps me cope’, and negative 
metacognitive beliefs about the uncontrollability and danger of worry, e.g. ‘When I start 
worrying, I cannot stop’. 
The study found metacognitive beliefs accounted for a significant proportion of the 
variance in both depression and anxiety, when controlling for demographic and clinical variables 
including level of fatigue. Negative metacognitive beliefs, lack of cognitive confidence and 
cognitive self-consciousness and the CAS emerged as significant independent statistical 
predictors of depression. Positive metacognitive beliefs, negative metacognitive beliefs and the 
CAS emerged as significant independent statistical predictors of anxiety.  
Overall, results provided support for the S-REF model. The relationship between positive 
metacognitive beliefs and depression was fully mediated by the CAS. Relationships between 
negative metacognitive beliefs and both depression and anxiety, and positive metacognitive 
beliefs and anxiety were partially mediated by the CAS.   
The paper is intended for submission to the British Journal of Health Psychology 
(Appendix B), selected due to the focus on all aspects of psychology related to health, including 
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the management of chronic illness. Findings are intended to have implications for clinical 
interventions, specifically aiming to reduce co-morbid anxiety and/or depression in people living 
with CFS/ME.  
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Abstract 
 
Objective: High levels of depression and anxiety are experienced by people living with Chronic 
Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). The psychological mechanisms that 
cause and maintain distress in this context are not well-understood. One such mechanism may be 
perfectionism, a multifactorial, transdiagnostic risk factor for various physical and mental health 
conditions. This systematic review aimed to assess the nature of the relationship between 
perfectionism and depression and/or anxiety (emotional distress), in people living with CFS/ME.  
Method: Systematic literature searches were completed using a combination of terms for 
‘perfectionism’, ‘emotional distress’ and ‘CFS/ME’. Inclusion was contingent upon publication in 
English in a peer-reviewed journal, and reporting of quantitative data pertaining to the 
relationship between perfectionism and depression and/or anxiety in adults (aged 18-65 years) 
with a clinical diagnosis of CFS/ME.  
Results: Seven studies, reported in eight papers, were included. Only one study examined the 
relationship between perfectionism and anxiety; the remainder focused on depression. Only 
maladaptive perfectionism was consistently associated with depression, with studies reporting 
moderate-strong correlations. Findings regarding other aspects of perfectionism were mixed. 
Methodological limitations in selected studies related to sample size justification and selection, in 
addition to control of potential confounders; no studies controlled for fatigue in assessing the 
relationship between perfectionism and anxiety/depression.  
Conclusion: Maladaptive perfectionism is associated with depression in patients with CFS/ME. 
The relationship between perfectionism and anxiety is under-researched in this patient group. 
Examining the dynamic interplay between maladaptive perfectionism, fatigue and both 
depression and anxiety may increase clinical understanding. This may be enhanced through 
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investigating psychological mechanisms through which the trait of perfectionism may influence 
distress.  
 
Key words: Chronic Fatigue Syndrome, Perfectionism, Anxiety, Depression, Emotional Distress. 
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Introduction 
 
Chronic Fatigue Syndrome (CFS) is a disabling long-term condition, characterized by 
medically unexplained, persistent fatigue which is new in onset, unalleviated by rest and 
exacerbated by physical or mental activity [1,2]. Historically, and across cultures, many terms 
describe CFS [3]. Although controversy surrounds whether CFS and Myalgic Encephalomyelitis 
(ME) are discrete or hybrid diagnoses [4, 5], this review uses the term ‘CFS/ME’, reflecting 
National Institute for Health and Care Excellence (NICE) guidelines [6] and current treatment 
pathways in the United Kingdom. 
Presently, there is no objective test or consistent bio-marker for CFS/ME [7] and 
consistent organic explanations remain elusive [8 - 10]. Whilst consensus exists regarding the 
centrality of fatigue, variations exist between diagnostic criteria regarding the number, type and 
severity of additional symptoms [8]. Prevalence estimates range between 0.2% and 2.6% of the 
general population [11, 12] dependent upon case definition [13]. Lifetime prevalence is 
approximately 0.83% [14]. Approximately three quarters of people with CFS/ME are female [15]. 
Peak incidence occurs between the ages of 40-49 [16]. Symptom severity varies considerably 
both between patients and over time [6], making prevalence estimates by severity problematic 
[17]. Approximately 60% of people experience ‘mild’ symptoms at any one time [18]. The 10-
29% most severely affected require significant bed rest and care [17]. Regardless of severity, full 
recovery is rare; 82% to 95% of people experience life-long symptoms [19, 20] and an increased 
need for health care provision [23].  
Onset can be triggered by acute physical and/or psychosocial stressors [24], suggesting the 
utility of a bio-psychosocial model in understanding CFS/ME [25]. This model has been criticised 
for its emphasis on psychological factors [26]. However, psychoneuroimmunology research 
indicates reciprocity between physiological functioning and emotional distress in several health 
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conditions [27], which could apply to CFS/ME [28]. Irrespective of aetiological debate, co-
morbid depression and/or anxiety are frequently experienced [29]. Between 36%-70% of patients 
experience depression [30,31] and 32%-57% experience anxiety [32,33]. These co-morbidities 
can lead to poorer prognosis [34] and potential exacerbation of physical impairment [35]. 
Understanding modifiable psychological processes linked to anxiety and depression in CFS/ME is 
necessary to develop more effective interventions. Perfectionism, a transdiagnostic risk factor for 
a range of physical [36] and mental health conditions [37 – 42] could be an important determinant 
of anxiety and depression in CFS/ME. 
Perfectionism is a relatively stable, multifactorial construct, consisting of excessive 
performance standards and critical self-evaluation [36, 39, 43]. A dual-process model of 
perfectionism differentiates between ‘adaptive’ and ‘maladaptive’ perfectionism [43, 44]; the 
former is motivated by a desire to achieve goals, whilst the latter is driven by a need to avoid 
failure [44, 45]. Adaptive and maladaptive perfectionism relate differentially to health and 
wellbeing [36]. Within the general population, depression and anxiety are positively correlated 
with maladaptive perfectionism [43, 46] whilst links with adaptive perfectionism are inconsistent 
[47]. 
Maladaptive perfectionism manifests in cognitive, emotional, behavioural, and 
physiological responses [48] which can lead to emotional and physical exhaustion, as well as 
physical symptoms through overburdening the stress response system [49-52]. Behavioural 
components of maladaptive perfectionism may be motivated by a fear of failing to meet 
standards, resulting in either anxiety-driven over-work [48] or procrastination where standards are 
impossible to meet [38, 53]. Perceived failure to meet the standards of an ideal self may increase 
vulnerability to depression, through overemphasizing productivity and accomplishment in 
assessing self-worth [54, 55]. The ensuing distress maintains vulnerability to physical symptoms 
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via prolonged autonomic arousal [24]. Once physically unwell, bursts of activity to meet 
unrealistic, pre-morbid standards are often punctuated by post-exertional malaise and the need to 
recuperate [56].   
Higher levels of maladaptive perfectionism occur in people living with CFS/ME 
compared to healthy controls [57]. Maladaptive perfectionism has also been positively associated 
with self-critical coping strategies and adjustment difficulties in this patient group [58]. 
Perfectionism is a shared risk factor for depression, anxiety [59] and CFS/ME [60,61], suggesting 
the prudence of investigating associations between perfectionism and depression/anxiety within a 
CFS/ME population. To date, however, research has primarily focussed on the relationship 
between perfectionism and fatigue [60, 62] and perfectionism as a predisposing factor to CFS/ME 
[61].  
Greater understanding of the relationship between perfectionism and depression/anxiety in 
the CFS/ME population may inform a ‘living well with chronic illness’ approach, tailored to 
individual presentation. This would seek to reduce the emotional distress experienced alongside 
physical symptoms regardless of aetiological debate, as well as promoting adjustment to physical 
illness and adaptive coping strategies. The aim of this systematic review, therefore, is to 
investigate the magnitude of the relationship between perfectionism and depression/anxiety in 
people living with CFS/ME.  
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Methods 
Conduct and Reporting  
Conduct and reporting adheres to recommendations by the Centre for Reviews and 
Dissemination (CRD) [63] and Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidance [64]. A protocol can be accessed at: 
https://www.crd.york.ac.uk/PROSPERO, ID: CRD4201912483. 
 
Search Strategy 
Four electronic databases (CINAHL, MEDLINE, Scopus, PsycINFO) were systematically 
searched for relevant peer-reviewed articles from their inception until December 2019, using the 
following search terms: chronic fatigue* OR myalgic encephalomyelitis OR CFS OR M.E OR 
post viral* OR post-viral* OR PVFS OR chronic fatigue and immune dysfunction* OR CFIDS 
OR neuromyasthenia OR benign myalgic encephalomyelitis OR akureyri disease AND depress* 
OR anxi* OR distress* OR affective* OR nervous* OR psychiatric* OR mood* OR emotion* 
OR mental* AND perfectionis*. To ensure results were not limited to particular study designs, 
methodological filters were not applied. Additional literature was sought through citation 
chaining; references of selected articles were examined, and forward searches were completed via 
the Google Scholar search engine. References of relevant systematic reviews identified during 
searching were also explored. Searches were updated in April 2020.  
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Study Selection  
 Screening was completed independently by two authors (AW and LOR). Relevance was 
assessed through simultaneous screening of titles and abstracts. Potentially relevant papers were 
examined in full. Where consensus could not be reached, views of the wider research team were 
sought. Inclusion was contingent upon: a) publication in English; b) publication in a peer 
reviewed journal; c) research participants being aged 18 to 65 years with a clinical diagnosis of 
either CFS, ME, Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS), Post Viral 
Fatigue Syndrome or Post Viral Syndrome; d) use of validated psychometric measures (or 
subscales of validated measures) to assess perfectionism and either depression, anxiety or a 
composite score (emotional distress); and e) reporting of quantitative, cross-sectional data 
pertaining to the relationship(s) between perfectionism and depression/anxiety/emotional distress. 
Intervention studies were included if they reported bivariate and/or multivariate analyses of 
variables pre-intervention; post-intervention data were excluded, as were retrospective reports.  
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PRISMA Diagram Summarising the Screening Process for Included Studies 
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Assessment of Risk of Bias  
 Included papers were assessed independently by two authors (AW and LOR) for risk of 
bias using a tool (Appendix C) adapted from the Agency for Healthcare Research and Quality 
[65, 66]. The tool assesses risk of bias in studies across a range of domains relevant to research 
with physical health populations. Criteria relating to intervention study follow up data were 
removed to ensure relevance to this study. Unbiased selection of cohort criteria was adapted to 
reflect a representative sample of the CFS/ME population.  Criteria for cohort description and 
analysis of confounders were adapted to include CFS/ME specific factors.  
Resolution of uncertainty was reached through either consensus or consultation with the 
wider research team. In line with CRD guidance [63], studies were not excluded where risk of 
bias was indicated; however, this was considered when interpreting results. Reviewers were not 
blinded to the authors, institutions, or journals of included studies. 
 
Data Extraction and Analysis   
Extraction of relevant clinical, demographic and methodological data was completed by 
AW and checked for accuracy by a second author (LOR). Where studies included control groups, 
only data for the CFS/ME population were extracted. Data extracted from linked studies were 
reported as a single study, listing all relevant publications. Where multiple analyses were 
reported, data from the following were extracted: a) bivariate analyses examining associations 
between measures of perfectionism and emotional distress (anxiety and/or depression); and/or b) 
multivariate analyses, in which the effects of potential confounders on the aforementioned 
correlations were controlled for. Where necessary, authors were contacted to obtain missing data. 
Due to the range of psychometric measures and subscales used across a relatively small number 
of studies, meta-analysis was not possible.  
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Results 
 
The main characteristics of the included studies [67-74] are detailed in Table 1. An overall 
sample of 702 participants was reported upon. All studies were conducted in Europe. Two used a 
longitudinal design [70, 72]; the remainder were cross-sectional. All studies recruited samples of 
patients using CDC diagnostic criteria [2]. Four studies specified additional criteria to increase 
diagnostic rigour [70, 71, 73, 74]. Four studies, reported in five papers [67, 68, 69, 71,72], 
reported mean time since illness onset, which ranged from 36 to 72 months.    
Six studies, reported in seven papers, reported on educational attainment [67, 68, 69 
70,71,73,74]. Approximately half of the overall sample had completed either secondary or tertiary 
education, and approximately one third had completed higher education.  
Four papers reported mean depression severity [70,71,73,74]; all exceeded minimum 
thresholds for clinical caseness as measured by either the Beck Depression Inventory [75] (> 9) or 
the Hospital Anxiety and Depression Scale [76] (> 8); Two papers [67, 69] reported proportion of 
participants meeting at least minimum clinical cut-offs for depression, ranging between 33-
40.1%. A single study [67] reported on the percentage participants meeting clinical cut of scores 
for anxiety (43%).  
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Table 1 
 
Characteristics of Studies (n = 7) 
 
Study Characteristics Participant Characteristics   
Author Design  Location  Sampling 
method 
n Female  
(%) 
Age, 
mean          
(SD)        
Range 
Highest 
educational 
attainment 
(percentage) 
Exclusion of 
co-morbid 
psychiatric 
diagnoses? 
Diagnostic 
/assessment 
criteria 
specified 
Distress 
Score 
(SD) 
Measure 
 
Time since 
onset in 
months 
mean   
 
Blenkiron et 
al., 1999 
[67] 
Cross -sectional UK Purposive 
 
40 60 49 
(median) 
21-66 
Median years 
in education 
since aged 16: 
5    
 
No  CDCa 33% met criteria 
for depression 
HADS-D 
(8 >) 
 
43%.met criteria 
for anxiety 
HADS-A 
(8 >) 
 
Depression 
36 
Kempke et 
al., 2011 [68 
& 69]1 
Cross-sectional  Belgium 
 
Purposive 
 
192 85.4 40.17 
(9.43) 
19–66 
Secondary/ 
Tertiary:  
49.2 
Higher 
Education: 
45.5 
n/s CDCa 
 
 
n/s 
BDIc 
 
40.1% met 
depression 
criteria. HADS-Db 
 
57.36 
Kempke et 
al., 2015 
[70] 
 
Longitudinal 
 
Belgium 
 
Purposive 
 
40 100 41.93 
(7.99) 
28—58 
 
 
Secondary/ 
Tertiary: 
51 
Higher 
Education: 
43.6 
 
 
 
 
 
 
 
Yes. 
Exclusions: 
‘psychiatric 
diagnoses which 
may explain 
fatigue’ 
 
 
 
 
 
 
CDCa 
Medical 
evaluation 
Depression 
8.72 
(3.86) 
HADS-D 
 
 
 
 
 
 
 
n/s 
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Table 1: continued  
 
 
Luyten et al., 
2006 [71] 
Cross-sectional  Belgium Purposive 
 
43 86 
 
39.1 
(7.91)      
22-58      
Mean: 1.09 c 
(SD .89) 
n/s 
 
CDCa 
Biological & 
Psychological 
Assessment. 
 
Depression 
11.88  (7.95)  
BDIc 
39.1 
 
Luyton et 
al., 2011 
[72] 
 
Longitudinal 
 
 
Belgium 
 
 
Purposive 
 
57 93 42.19  
(8.33) 
18-59 
n/s n/s CDCa  
 
Depression 
n/s      
BDIc 
72.36 
Valero et al., 
2013 [73] 
Cross-sectional  
 
 
Spain Purposive 
 
229 91.3 48.21 
(8.93) 
22-73 
Secondary/ 
Tertiary: 41.4              
Higher 
Education: 
20.2   
 
Yes. 
Exclusions: 
‘severe unstable 
psychiatric 
disorders’ d   
CDCa 
Medical 
evaluation. 
Psychiatric / 
Psychological 
assessment. 
 
Depression 
10.35  (4.95)  
HADS-D 
n/s 
Wood & 
Wessely., 
1999 [74] 
Cross-sectional  UK Purposive 
 
101 60.4 36.6 
(10.5) 
Secondary/ 
Tertiary:  
58.41                   
Higher 
Education: 
28.71       
n/s  CDCa 
UKoc 
Psychiatric 
assessment 
15.3    
BDI 
13.6    
BDIc 
e 
 
 
Note. BDI = Beck Depression Inventory [75]; BDIc = Beck Depression Inventory corrected (items 15, 16 & 17 removed due to symptomatic overlap); CDC = Centre for Disease Control criteria for 
CFS [2]; HADS-A = Anxiety subscale of Hospital Depression and Anxiety Scale [76]; HADS-D = Depression subscale of Hospital Anxiety and Depression Scale [76]; n/s = not specified; UKoc = 
UK operational criteria [77].   
 
Data reported to two significant figures where possible. 
 
 a Centre for Disease Control criteria for CFS [2] specifies the following as exclusions of diagnosis: ‘Any past or current diagnosis of major depressive disorder with psychotic or melancholic features; 
bipolar affective disorders; schizophrenia of any subtype; delusional disorders of any subtype; dementias of any subtype; anorexia nervosa; bulimia nervosa’; 
 
b Clinical cut off not specified. 
 
c 5-point scale: 1=primary; 0=lower secondary; 1=higher secondary; 2=undergraduate; 3=university 
  
d ‘Severe unstable psychiatric disorders’ specified: ‘a psychotic episode, a major depressive episode, maniac episode, substance use disorders and anorexia nervosa’; 
 
 e Authors state a median number of months: 3621-58. 
 
 1 linked studies [68 & 69]  
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Assessment of Risk of Bias  
 
The assessment of risk of bias is shown in Table 2. The main limitations relate to sample 
size justification and selection, in addition to control of potential confounders in analyses. All 
studies used the CDC diagnostic criteria [2]; whilst frequently used in research and clinical 
diagnosis, this arguably captures a larger, more heterogeneous group, with a broader range of 
symptom severity than captured by more stringent diagnostic criteria [78]. Studies recruited from 
specialist CFS health services, with most sampling consecutive patients [68, 69, 70,72,73,74]. 
Whilst increasing rigour regarding diagnosis confirmation, this introduces a selection bias; 
samples reflect a subset of patients, willing and able to access mainstream health services at a 
particular time point. Four studies, reported in five papers, recruited from the same hospital-
based CFS centre [68 - 72]. Only one study randomly selected participants from a waiting list 
[67]. Subsequently, generalizability of findings to the wider CFS/ME population is questionable. 
No study reported a sample size calculation, rendering consideration of statistical power 
problematic and suggesting potential Type 1 errors. Descriptions of demographics were partial. 
Four studies [68, 71, 72, 74] used a corrected form of the BDI [75] with items 15, 16 and 17 
removed due to symptomatic overlap (BDIc). Two papers partially controlled for cross-sectional 
confounders when analysing the relationship between perfectionism and depression [69, 71]; 
however, time since CFS/ME onset, physical and cognitive symptom severity were not 
accounted for. 
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Table 2 
 
Assessment of Risk of Bias 
 
Author Unbiased 
selection 
of cohort? 
Sample size 
calculation 
Adequate 
description 
of cohort 
Validated 
measure of 
perfectionism 
 
Validated 
measure of 
depression 
and/ anxiety 
 
Recognised 
diagnostic 
criteria / 
medical 
assessment 
for CFS 
 
Cross 
-sectional 
confounders 
Controlled 
for?  
Appropriate 
analyses 
Blenkiron 
et al. [67] 
 
Partially  n/s 
 
 
Partially Yes.  Yes. 
 
Yes No  Partially 
Kempke et 
al. [68]1 
 
Partially n/s Partially Yes Yes Yes No  Partially 
Kempke et 
al. [69]1 
Partially 
 
 
n/s Partially Yes Yes Yes Partially Partially 
Kempke et 
al. [70] 
 
Partially n/s Partially Yes Yes Yes No Partially 
Luyten et 
al. [71] 
Partially 
 
n/s Partially Yes.  Yes 
 
 
Yes Partially Partially 
Luyton et 
al. [72] 
Partially n/s Partially Yes Yes 
 
 
Yes No Partially 
Valero et 
al. [73] 
 
Partially  n/s Partially Yes Yes 
 
Yes No  Partially 
Wood & 
Wessely, 
[74] 
 
Partially  n/s Partially Yes Yes Yes No Partially 
Note. n/s = not specified 
 
1 linked studies [68 & 69] 
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Assessment of Perfectionism 
 
All studies used self-report measures of perfectionism, most frequently the Frost 
Multidimensional Perfectionism Scale (MPS-F) [79]. Subscales assess ‘concern over 
mistakes’; ‘doubts about actions’; ‘personal standards’; ‘organisation’ (a preference for 
orderliness and organization); ‘parental expectations’ and ‘parental criticism’ (as perceived 
by the individual); plus a composite score. Two papers [69,73] measured a latent variable of 
‘maladaptive perfectionism’, using the ‘concern over mistakes’ and ‘doubts about actions’ 
subscales [46, 79]. One study [67] used the Multidimensional Perfectionism Scale (MPS) 
[80], which measures ‘self-orientated’; ‘other-orientated’; and ‘socially prescribed’ 
perfectionism, plus a composite score. Two studies [70, 72] employed the ‘self-critical 
perfectionism’ subscale of the Depressive Experiences Questionnaire (DEQ) [81].  
 
Assessment of Depression and Anxiety  
All studies assessed depression, using either the HADS or a corrected version of the 
BDI [75] (Table 3). One study [67] assessed both anxiety and depression, using the HADS. 
No study used measures specifically designed to assess anxiety of depression in people living 
with CFS/ME.  
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Table 3 
 
Measures of Dependent and Outcome Variables 
 
Variable Measure Used by  
  
Subscales 
Perfectionism  MPS 
 
Blenkiron et al. [67] Self-orientated; other-orientated; socially prescribed; total perfectionism 
 
 MPS-F 
 
Kempke et al. [68]1 Concern over mistakes (CM); doubts about actions (DA); personal standards  
(PS) 
 
PS = ‘adaptive perfectionism’ 
 
CM+DA = ‘maladaptive perfectionism’  
                   
  Kempke et al. [69]1 
 
Concern over mistakes (CM); doubts about actions (DA) 
 
CM+DA = ‘maladaptive perfectionism’  
 
  Luyten et al. [71] 
 
Personal standards (PS); concern over mistakes (CM); doubts about actions  
(DA); organisation  (O); parental expectations  (PE); parental criticism (PC)  
 
  Valero et al. [73] 
 
CM+DA = ‘maladaptive perfectionism’  
                   
  Wood & Wessely [74] 
 
Personal standards (PS); concern over mistakes (CM); doubts about actions  
(DA); organisation  (O); parental expectations  (PE); parental criticism (PC)  
 
Total perfectionism: (CM+DA+PS+PE+PC) 
 
 DEQ 
 
Kempke et al. [70] Self-critical perfectionism (S-CP) 
  Luyton et al.  [72] 
 
Self-critical perfectionism (S-CP) 
Depression  HADS  Blenkiron et al. [67]  
 
HADS-D 
  Kempke et al. [69]1 HADS-D 
 
  Kempke et al. [70] 
 
HADS-D 
  Valero et al. [73] 
 
HADS-D 
 BDIc Kempke et al. [68]1 
 
N/A 
  Luyten et al. [71] 
 
N/A 
  Luyton et al. [72] 
 
N/A 
  Wood & Wessely [74] 
 
N/A 
Anxiety HADS Blenkiron et al. [67] 
 
HADS-A 
Note. BDIc = Beck Depression Inventory [75] corrected (items 15, 16 & 17 removed due to symptomatic overlap); DEQ = Depressive 
Experiences Questionnaire [81]; HADS = Hospital Anxiety and Depression Scale [76]; HADS-A = Hospital Anxiety and Depression 
Scale, anxiety subscale; HADS-D = Hospital Anxiety and Depression Scale, depression subscale; MPS = Multidimensional Perfectionism 
Scale [80]; MPS-F = Frost Multidimensional Perfectionism Questionnaire [79]; N/A = not applicable to study. 
 
 1linked studies [68 & 69]. 
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Adaptive and Maladaptive Perfectionism  
Statistically significant positive associations were evidenced between depression and 
both ‘concern over mistakes’ and ‘doubts about actions’, as well as the latent variable 
‘maladaptive perfectionism’ [68, 69, 71, 73, 74]. Associations between depression and 
‘doubts about actions’ ranged from .46 to .60; associations between depression and ‘concern 
over mistakes’ ranged between .35 and .60. When controlling for all perfectionism subscales 
using the MPS-F, Luyton et al. [71] found ‘doubts about actions’ was significantly associated 
with depression severity (β = .47, p < .04). Kempke and colleagues [69] found ‘maladaptive 
perfectionism’ was significantly associated with depression (β = .34, p < .001); however, this 
association was no longer significant when controlling for self-esteem (β = .8, ns), which 
fully mediated the relationship between perfectionism and depression.  It is important to note 
that cross sectional data were used for the mediation analysis which means that a causal 
relationship cannot be assumed. Mixed support was found for the association between 
depression and ‘personal standards’ (also termed ‘adaptive perfectionism’); the significant 
moderate associations reported by Kempke and colleagues (r =.33, p <.001) [68] and Luyton 
and colleagues ( r = .32, p <.05) [71] were not found by Wood and Wessely (r = .15, p = .10) 
[74]. 
 
Organisation  
Of the two studies that looked at association depression and ‘organisation’, one found 
a significant positive correlation [71] (r =.41, p< .01), whilst the other found no relationship 
(r =.02, p = .99) [74]. When controlling for all other factors of perfectionism, Luyton and 
colleagues [71] found ‘organisation’ was a significant and positive statistical predictor of 
depression severity (β = .43, p< .01). 
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Parental Factors of Perfectionism  
Small, non-significant associations were found between depression and ‘parental 
expectations’ (r = .18, ns; r = .12, p = .19) [71, 74]. However, the small significant 
association between depression and ‘parental criticism’ (r = .18, p = .05) reported by Wood 
and Wessely [74] was not found by Luyton and colleagues (r = .20, ns) [71].  
 
Self-Critical Perfectionism  
Findings regarding the association between depression and ‘self-critical 
perfectionism’ were mixed. A small, non-significant association (r =.22, ns) was reported by 
Kempke and colleagues [70]. However, Luyton and colleagues, [72] found a significant, 
moderate correlation (r= .48, p< .001).  
 
Self-Orientated; Other-Orientated and Socially Prescribed Perfectionism  
The single study [67] assessing anxiety found no significant associations with either 
‘self-orientated’; ‘other-orientated’ or ‘socially prescribed’ perfectionism.   
 
Total Perfectionism  
Two studies reported a composite perfectionism score: one using the MPS [67] and 
one using the MPS-F [74]. The former reported no significant association between total 
perfectionism and either depression (r = .07, ns) or anxiety (r = -.01, ns) [67]. The latter [74] 
reported a significant association with depression (r =.37, p < .001), but excluded the 
‘organisation’ subscale.  
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Table 4. 
 
Main Findings – Associations Between Perfectionism and Depression and Anxiety. 
 
Perfectionism Type 
 
Authors Method of Assessing 
Perfectionism (Subscales) 
Statistical Analyses Effect Size: 
Depression 
 
(p) 
 
Effect Size: 
Anxiety 
 
(p) 
 
‘Maladaptive’ 
 
 
Kempke et al. [69]1 
 
 
Valero et al. [73] 
 
MPS-F (CM; DA) 
 
 
Pearson’s correlation 
 
 
r =.48***   
(p<.001) 
 
r = .42**   
(NR)  
 
N/A 
 
 
N/A  
‘Self-critical’ Luyton et al. [72] 
 
 
Kempke et al., [70] 
DEQ (SC-P)  r = .48***  
(p<.001) 
 
r =.22  
(ns, NR)      
N/A 
 
 
N/A  
Total  
 
 
Blenkiron et al. [67] 
 
 
Wood & Wessely [74] 
MPS 
 
 
MPS-F (CM, DA, PS, PE, PC) 
 r = .07   (ns, 
NR) 
 
r =.37*** 
(p<.001) 
   
r = -.01 
(ns, NR) 
 
N/A 
 
Self-orientated  Blenkiron et al. [67] MPS (SO) Spearman’s correlation r = -.06   
(ns, NR)   
r = -.69 
(ns, NR) 
  
Other-orientated   MPS (OO)  r = -.13 
(ns, NR)   
     
r = -.22 
(ns, NR)  
Socially prescribed   MPS (SP)  r = .23   
(ns, NR)      
   
r = .06 
(ns, NR)  
‘Adaptive’ 
Personal Standards 
Kempke et al. [68] 1 
 
 
Luyton et al. [71] 
 
 
Wood & Wessely [74] 
MPS-F (PS) 
 
Pearson’s correlation 
 
r =.33***  
(p<.001) 
 
r = .32*  
(NR)      
 
r = .15   
(p = .10)   
N/A 
 
 
N/A 
 
 
N/A 
Concern over Mistakes Kempke et al. [68] 1 
 
 
Kempke et al. [69] 1 
 
 
Luyton et al. [71] 
 
 
Wood & Wessely [74] 
MPS-F (CM) 
 
 r = .60***  
(p<.001) 
   
r = .40*** 
(p<.001) 
      
r = .43**  
(NR) 
 
r = .35*** 
(p<.001) 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
Doubts about Actions 
 
Kempke et al. [68]1 
 
 
Kempke et al. [69]1 
 
 
Luyton et al. [71] 
 
 
Wood & Wessely [74] 
 
  
MPS-F(DA) 
 
 r =.60***  
(p<.001) 
    
r =.53*** 
(p<.001) 
      
r =.51*** 
(p<.001) 
   
r = .46*** 
(p<.001)     
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
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Table 4. continued 
 
Organisation Luyton et al. [71] 
 
 
Wood & Wessely [74] 
MPS-F (O) 
 
 r =.41**  
(NR) 
  
r = .02   
(p = .99)    
N/A 
 
 
N/A 
Parental Expectations 
 
Luyton et al. [71] 
Wood & Wessely [74] 
MPS-F (PE) 
 
  r = .18  
(ns, NR)  
      
r = .12   
(p = .19)  
N/A 
 
 
N/A 
Parental Criticism Luyton et al. [71] 
Wood & Wessely [74] 
 
MPS-F (PC) 
 
  r= .20  
(ns, NR)  
   
  
r = .18*  
(p = .05)    
N/A 
 
 
 
N/A 
 
Note. CM = concern over mistakes; DA =doubts about actions; DEQ = Depressive Experiences Questionnaire [81]; MPS = Multidimensional 
Perfectionism Scale [80]; MPS-F= Frost Multidimensional Perfectionism Questionnaire [79]; N/A = not applicable to study; NR = not reported; ns = non-
significant; O = organisation; OO = other-orientated; PC = parental criticism; PE = parental expectations; PS = personal standards; S-CP = self-critical 
perfectionism; SEM = structured equation modelling; SO = self-orientated; SP= socially prescribed. 
 
 * p < .05; **p < .01; ***p < .001. Exact p values reported where stated in publication. 
 
1Linked studies [68 & 69]. 
 
2MPS-F minus ‘organisation’ subscale. 
 
 
 
Table 5 
 
Main Findings from Multi-Variate Analysis: Depression 
 
Author Analysis Variables Significant findings 
  Perfectionism 
(factor) 
Measure 
Psycho- 
social 
Non- 
Psycho- 
Social 
 
 
      
Kempke et al. [69]1 
 
RA MAL (CM, DA) Self-esteem None None 
 
Luyten et al. [71] HMRA PS; CM; DA; O: PE; PC None None Organisation:  
β = .43, p< .01 
Doubts about Actions: 
β = 47., p< .04 
 
Note. CM = concern over mistakes; DA= doubts about actions; HMRA = hierarchical multiple regression analysis; MAL = maladaptive 
perfectionism; O = organization; PC = parental criticism; PE parental expectations; RA: regression analysis.  
 
1 linked study [68 & 69]. 
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Discussion 
 
This systematic review examined the relationship between perfectionism and 
emotional distress (depression and/or anxiety) in people living with CFS/ME. Systematic 
searches revealed a paucity of data regarding anxiety, as well as heterogeneity in measures of 
both depression and perfectionism. Results therefore primarily focus on associations between 
depression and specific aspects of perfectionism in people living with CFS/ME.  
When treated as a unidimensional construct, perfectionism was not consistently 
associated with depression. However, ‘maladaptive perfectionism’, and the composite 
subscales of ‘doubts about actions’ and ‘concern over mistakes’ were consistently associated 
with depression [68, 69, 71, 73, 74]. Nevertheless, only two studies [69, 71] controlled for 
cross-sectional confounders; one of these being other factors of perfectionism [71]. 
Subsequently, it is not known whether the relationship between maladaptive perfectionism 
and depression would hold once other variables are controlled. A single study [69] found 
‘maladaptive perfectionism’ was no longer a significant statistical predictor of depression 
severity, when controlling for self-esteem. However, greater consideration of the  
relationships between distress and both pre-and post-morbid perfectionism and self-esteem is 
needed. 
Findings regarding the association between depression and other factors of 
perfectionism were mixed. This likely reflects the smaller number of studies eligible for 
inclusion in this review. However, in the case of adaptive perfectionism, this is consistent 
with psychological theory and existing literature [49]; ‘adaptive perfectionism’ may confer 
some psychological benefits [46, 82]. Mixed findings regarding ‘adaptive perfectionism’ may 
be considered alongside findings by Deary and Chalder [60], who concluded ‘adaptive 
perfectionism’ may cease to be adaptive in People living with CFS/ME, due to its correlation 
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with ‘maladaptive perfectionism’; striving to achieve standards may in fact trigger self-doubt, 
self-criticism and worry [60, 83].  
 
Methodological Limitations and Implications for Future Research 
Analysis of cross-sectional data from seven studies offers preliminary evidence that 
‘maladaptive perfectionism’ is associated with depression in people living with CFS/ME. 
Whilst the hypothesized causal role of ‘maladaptive perfectionism’ is grounded in theory and 
previous research [37, 39, 46, 54], firm conclusions cannot be drawn regarding 
generalisability or causality without further research.  
 Divergent findings may have resulted in part, from differential measurements of both 
perfectionism and distress. At the same time, all primary models of trait perfectionism and 
the related psychometric measures were not represented in the selected studies. Notably 
absent was the Almost Perfect Scale-Revised [84], which measures ‘high standards’, ‘order’, 
and ‘discrepancy’. Whilst the former two subscales overlap with factors measured by the 
MPS and MPS-F, the unique factor of ‘discrepancy’ refers to the disparity between standards 
and the degree to which these are perceived to be achieved [84]. This is likely to be relevant 
in the relationship with depression/anxiety; people living with CFS/ME may be particularly 
vulnerable due to the inability to meet pre-morbid standards. Measures which encompass 
multiple subscales [85] may enable a broader focus in future research, whilst maintaining 
methodological consistency.  
Included studies did not adequately consider or test a range of mechanisms through 
which perfectionism and distress may be linked. Similarly, the search identified studies 
measuring perfectionism at the trait level only. Future studies may also usefully examine the 
potential mediating role of perfectionistic cognitions [86 - 89].  
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The inclusion of peer reviewed articles only sought to ensure quality. However, this 
may have introduced a publication bias [90]. Language, selection or cultural bias may also 
have been introduced by the inclusion of only articles published in English. Similarly, all 
studies were conducted in Europe.  
Participants were predominantly females in their thirties and forties, reflecting what is 
known about the demographics of CFS/ME [15, 16]. Generalisability is nevertheless unclear, 
as the sample consisted solely of people in receipt of services and diagnosed using the CDC 
criteria. Whilst the single diagnostic criteria (CDC) facilitated direct comparison across 
studies, this arguably captured a heterogenous group [78]. Further research may usefully 
examine the relationship between perfectionism and emotional distress in relation to 
categories of CFS/ME symptom severity. 
 Further research is needed which specifically focusses on the associations between 
perfectionism and emotional distress in CFS/ME. Examining the interplay between 
‘maladaptive perfectionism’, fatigue and both depression and anxiety would enhance clinical 
understanding. Further insight may be gained through examining psychological mechanisms 
through which perfectionism may affect levels of depression and anxiety. Longitudinal 
designs would facilitate greater confidence in concluding causality. Prospective studies may 
usefully track patient groups at risk of developing CFS/ME, such as those experiencing 
glandular fever [61]. This would enable analysis of pre- and post-morbid perfectionism and 
emotional distress. Samples including patients both engaged and no longer engaged in 
mainstream health services may be more representative of the CFS/ME population. 
Consistency of measures would further enable development of the evidence base. In 
researching ‘concern over mistakes’ and ‘doubts about actions’, methodological rigour may 
be enhanced through statistically controlling for cognitive symptoms of CFS/ME [91], which 
may interact with these factors of perfectionism. 
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Theoretical and Clinical Implications 
 Divergent findings regarding the relationship between depression and different 
aspects of perfectionism corroborated its status as a multifactorial construct [36]; treatment as 
a unidimensional concept would risk masking the differential impact of adaptive and 
maladaptive factors upon depression and/or anxiety.  
A single study found self-esteem mediated the relationship between maladaptive 
perfectionism and depression. Whilst further research is needed to corroborate this outcome, 
this is consistent with psychological theory; perceived failure to meet standards of an ideal 
self may increase depression vulnerability, via self-esteem being overly dependent upon 
productivity and accomplishment [54]; This is consistent with evidence of low self-esteem in 
people living with CFS/ME [57], and indicates the potential relevance of ‘discrepancy’ [84] 
as a factor of perfectionism.  
‘Maladaptive perfectionism’ was consistently associated with depression in CFS/ME, 
indicating these provisional findings could have implications for further research. Clinical 
recommendations are based on prospective findings from cross-sectional research, which 
require corroboration from further studies. 
Rather than targeting high personal standards per se, therapeutic techniques 
addressing ‘concern over mistakes’ and ‘doubts about actions’ may be efficacious in reducing 
depression. This may reduce the somatic overlay, which is likely to exacerbate fatigue. 
Clinical consideration would be required on an individual basis, regarding the relationship 
between ‘doubts about actions’, ‘concern over mistakes’ and the level of cognitive symptoms 
experienced [91]; difficulties with memory and concentration may further increase such 
perfectionistic concerns, which may drive checking behaviours and increased energy 
expenditure. This may push people beyond their ‘energy envelope’ [92]. 
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Targeting ‘maladaptive perfectionism’ in management programmes may facilitate 
more adaptive coping strategies and adjustment to living with chronic illness. This may 
potentially reduce the risk of ‘boom and bust’ activity patterns [93] and checking behaviours, 
triggered by a desire to meet unrealistic, self-imposed and possibly pre-morbid standards. 
This may be important for relapse prevention, regarding both CFS and co-morbid depression. 
Where psychometric measures indicate relevance, psychoeducation may facilitate 
understanding of the advantages and disadvantages of perfectionism and give a focus for 
change. This may be particularly important for those either retaining or returning to some 
degree of employment or educational activity; perfectionistic concerns are likely to be 
triggered more easily in these environments.  
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Conclusions 
To our knowledge, this is the first systematic review to examine the relationship 
between different aspects of perfectionism and emotional distress in people living with 
CFS/ME. Findings suggest the association between perfectionism and anxiety is an under-
researched area in this patient group. However, maladaptive perfectionism was consistently 
found to be associated with depression. It would be clinically meaningful to establish whether 
there are links between maladaptive perfectionism, fatigue and both depression and anxiety. 
Understanding the dynamic relationships between these variables may ultimately contribute 
to the development of efficacious therapeutic interventions, as part of a ‘living well with 
chronic illness’ approach.  
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Abstract 
 
Objectives: Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) 
frequently experience comorbid depression and anxiety. The transdiagnostic Self-Regulatory 
Executive Function (S-REF) model proposes that metacognitive beliefs activate and maintain 
depression and anxiety, both directly and indirectly by driving a cognitive attentional 
syndrome (CAS). However, the fit of the S-REF model to understanding depression and 
anxiety in patients with CFS/ME has not yet been examined. Design: A cross-sectional 
design using multiple self-report measures. Method: Adults with a self-confirmed diagnosis 
of CFS/ME (N=235) completed measures of depression, anxiety, fatigue, metacognitive 
beliefs and use of the CAS. Data were analysed using hierarchical regression modelling and 
mediation analyses. Results: When controlling for demographic and clinical variables, 
metacognitive beliefs accounted for an additional 8.2 % of the variance in depression and an 
additional 14.5 % of the variance in anxiety. Specific metacognitive beliefs domains made 
independent contributions to the final models for both depression and anxiety. The 
relationship between positive metacognitive beliefs and depression was fully mediated by the 
CAS. Relationships between negative metacognitive beliefs and both depression and anxiety, 
and positive metacognitive beliefs and anxiety were partially mediated by the CAS.  
Conclusions: Metacognitive beliefs are both directly and indirectly associated with 
depression and anxiety in people living with CFS/ME. If corroborated by longitudinal 
evidence, future studies should test the clinical impact of targeting metacognitive beliefs and 
processes upon depression and anxiety.  
 
Keywords: Chronic Fatigue Syndrome; Myalgic Encephalomyelitis; Depression; Anxiety; 
Metacognitive Beliefs; Cognitive Attentional Syndrome.  
52 
 
 
 
Summary of Relevant Literature 
 
 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a complex, 
heterogenous clinical presentation (Martín-Martínez & Martín-Martínez, 2019) with 
considerable debate surrounding its aetiology, diagnostic nomenclature and treatment 
(Brurberg et al., 2014; Jason et al., 2014). Prevalence is estimated to be between 0.2% and 
2.6% (Nacul et al., 2011; Reyes et al., 2003), dependent upon diagnostic criteria (Johnston et 
al., 2013). The predominant symptom is persistent, medically unexplained fatigue of new 
onset, which is unalleviated by rest, exacerbated by mental or physical activity, and which 
causes significant impairment (Fukuda et al., 1994). A multisystemic condition is indicated 
by the broad range of additional symptoms, including endocrinological, immunological, 
neurological and cognitive dysfunction (Cortes Rivera et al., 2019; Glassford, 2017). The 
latter, subjectively experienced as exaggerated mental fatigue, is proposed to be a dynamic 
interplay between cognitive, physiological, and perceptual factors (Ocon, 2013).  
Significant variability exists in symptom presentation and severity (Zaturenskaya et 
al., 2009), with the latter categorized as either mild, moderate, severe or very severe (Cox & 
Findley, 1998; 2000; National Institute for Health and Care Excellence, [NICE, 2007]). 
Those most severely affected are confined to bed and become highly sensitive to light and 
sound (Strassheim et al., 2017). In mild cases, people are able to maintain pre-morbid 
activities such as employment, despite experiencing symptoms; however, this often comes at 
the expense of leisure and social time (Cox & Findley, 1998; 2000), impacting significantly 
upon quality of life and emotional wellbeing. Prognosis estimates vary (Cortes Rivera et al., 
2019), reflecting the heterogeneity of the condition, as well as differential criteria for 
recovery (Cairns & Hotopf, 2005). Symptom improvement is more common than full 
recovery, with estimates of the latter being less than 10% (Cairns & Hotopf, 2005; Vercoulen 
et al., 1996). 
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People living with CFS/ME frequently experience comorbid depression and anxiety 
(Larkin & Martin, 2017), with prevalence estimates of 36%-70% (Fuller-Thomson & 
Nimigon, 2008; Iwase et al., 2008) and 32%-57% (White et al., 2011; Fischler et al., 1997) 
respectively. By comparison, point prevalence for common mental health difficulties is 
approximately 17% of the general population, with 3.3% reporting depression, 5.9% 
reporting generalized anxiety and 7.8% reporting mixed anxiety and depression (McManus et 
al., 2016). However, levels of depression and anxiety do not linearly increase with CFS 
symptom severity (Janal, Ciccone, & Natelson, 2006), indicating that other factors may 
mediate the relationship between fatigue and depression and anxiety. 
 Comorbid mental health difficulties are associated with poorer prognosis (Cairns & 
Hotopf 2005) and depression is an important predictor of CFS treatment outcome (Kempke et 
al., 2010). However, current psychological interventions primarily seek to reduce fatigue 
levels and increase physical functioning (White et al., 2011), which can alleviate anxiety and 
depression as a secondary outcome (Price et al., 2008).  
Recommended in NICE Guidelines (2007) for CFS/ME, traditional Cognitive 
Behavioural Therapy (CBT) focusses on restructuring ‘dysfunctional illness perceptions’ and 
beliefs, and reversing behavioural avoidance (Geraghty et al., 2019). Critics argue that the 
model underpinning CBT discounts the lived experience of patients, as well as the growing 
evidence of organic pathophysiology in CFS/ME (Geraghty et al., 2019). NICE guidelines 
are under review following concerns regarding the limited efficacy and potential harm of 
CBT, including increased distress in some cases (Laws, 2017; Vink & Vink-Niese, 2019). 
The ME Association (2015) proposes the role of psychological therapy should be limited to 
treating co-morbid issues such as depression and anxiety, and to promote effective coping 
with the impact of physical symptoms. Greater understanding of psychological mechanisms 
underpinning depression and anxiety are therefore needed to facilitate the development of 
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effective and acceptable therapeutic interventions; given the controversy, acceptability to the 
patient population is vital when considering potential treatment modalities, due to 
implications for uptake and adherence (Price et al., 2008).  
Whilst CBT could focus specifically on alleviating co-morbid depression and anxiety, 
Metacognitive Therapy (MCT; Wells, 2009) may be more appropriate for a ‘living well with 
chronic illness approach’. People with CFS/ME frequently experience CBT as invalidating 
due to its focus on illness perceptions and beliefs (Geraghty & Esmail, 2016; ME 
Association, 2015). Within the context of physical health, ‘negative thoughts’ may well 
reflect accurate and understandable fears regarding the illness and its’ impact (Cherry et al., 
2019) and, in the case of CFS/ME, additional concerns may include diagnostic and 
prognostic uncertainty (Ware, 1992; Whitehead, 2006). Rather than questioning the validity 
of negative thoughts themselves, MCT targets the psychological process through which 
patients engage with these thoughts, namely worry and rumination.  
MCT is an effective treatment for a range of affective and anxiety disorders 
(Normann et al., 2014), in addition to emotional distress within physical health populations 
(Elzami et al., 2015; Fisher et al., 2019; Mirhosseini et al., 2015). This suggests the potential 
utility of MCT in treating co-morbid depression and anxiety in CFS/ME. However, prior to 
evaluating the intervention, it is necessary to test predictions of the underlying theory in this 
patient group.   
MCT is based upon the trans-diagnostic Self-Regulatory Executive Function (S-REF) 
model (Wells & Matthews 1994). According to this model, prolonged distress does not result 
from thought content or CFS/ME-related appraisals per se, but rather metacognitive beliefs or 
‘thinking about thinking’. Metacognitive beliefs drive unhelpful thought processes and 
responses, termed the cognitive-attentional syndrome (CAS; Wells & Matthews 1994). The 
CAS consists of perseverative thinking, attentional focus upon threat, and maladaptive 
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cognitive and behavioural coping strategies, such as thought suppression and reassurance 
seeking. These patterns arise in response to perceived cognitive, behavioural, or emotional 
triggers, all of which may relate to physical illness.  
Two types of metacognitive belief about worry/rumination are theorised to be of 
particular significance in activation and maintenance of the CAS via differential pathways 
(Wells & Matthews, 1994); positive metacognitive beliefs (PMCBs) about the usefulness of 
worry, such as ‘worrying helps me cope’, and negative metacognitive beliefs (NMCBs) about 
the uncontrollability and danger of worry, such as ‘when I start worrying, I cannot stop’. 
PMCBs indirectly cause distress by promoting the use of worry/rumination as coping 
strategies. NMCBs about the uncontrollability and dangerousness of worry cause distress 
both directly and indirectly. This is because they are, themselves, distressing and lead to 
unhelpful cognitive self-regulation patterns, such as thought suppression and avoidance. 
Furthermore, efforts to control worry may be deemed futile where it is conceived as 
uncontrollable. Other metacognitive beliefs theorised to contribute to activation and 
maintenance of the CAS include cognitive self-consciousness, need to control thoughts, and 
lack of cognitive confidence. MCT aims to interrupt the CAS and modify metacognitive 
beliefs (Wells, 2009; 2013).  
Metacognitive processes are implicated in a wide range of psychological disorders 
(Wells, 2013). Preliminary evidence indicates the role of metacognitive processes in the 
emotional distress experienced by physical health populations including cancer (Cook et al., 
2015; Fisher et al., 2018) diabetes (Purewal & Fisher, 2018), epilepsy (Fisher, Cook, & 
Noble, 2016) multiple sclerosis (Heffer-Rahn & Fisher, 2018) and Parkinson’s disease (Allott 
et al., 2005; Brown & Fernie, 2015; Fernie et al., 2015).  
Metacognitive processes are activated in response to physical symptoms in people 
with CFS/ME (Maher-Edwards et al., 2012). These processes include attentional focus on 
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health-related threat stimuli (Hou et al., 2008), somatic information processing (Moss-Morris 
& Petrie, 2003), and high levels of worry (Aggarwal et al., 2006). Research has primarily 
focussed upon the role of metacognitive processes in maintaining physical symptoms 
(Maher-Edwards et al., 2011; Maher-Edwards et al., 2012). However, it is acknowledged that 
these processes are also likely to lead to an increase in negative affect (Maher-Edwards et al., 
2012; Sohl & Friedberg, 2008).  
Despite preliminary evidence indicating associations between metacognitive beliefs 
and depression/anxiety in people with CFS (Maher-Edwards et al., 2011), this relationship 
has not been investigated whilst controlling for demographic characteristics and symptom 
severity. Furthermore, to our knowledge, there is no existing research regarding whether the 
CAS mediates the relationship between metacognitive beliefs and distress in people with 
CFS/ME. This study therefore investigates the relationships between metacognitive beliefs, 
the CAS and anxiety and depression in people with CFS/ME. Specifically, we hypothesise 
that:  
 
1. Symptom severity (fatigue) will be positively correlated with depression and anxiety.  
2. Metacognitive beliefs will be positively correlated with depression, anxiety and 
fatigue.  
3. Metacognitive beliefs will account for a significant proportion of the variance in 
depression and anxiety, after controlling for fatigue and demographic variables.  
4. The relationship between metacognitive beliefs and both depression and anxiety will 
be mediated by the CAS. 
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Method 
Design 
The study used a cross-sectional design, with data collected using multiple self-report 
measures. 
Participants  
Participants were 235 people from the United Kingdom who met the following 
criteria: i) a self-confirmed clinical diagnosis of CFS/ME; ii) aged between 18 and 75 years; 
and iii) the ability to understand written English.  
 
Procedure 
The study was sponsored by the University of Liverpool (Appendices D & E) and 
ethical approval was granted by the Heath Research Authority (IRAS reference: 253333, 
Appendix F). Participants were recruited from three specialist CFS/ME NHS clinics in the 
United Kingdom (n = 16) and online via CFS/ME support groups and related social media 
pages (n = 219). In respect of recruitment from the NHS, eligible patients were approached 
by clinical staff during routine appointments or groups. Posters (Appendix G) and consent to 
contact forms (Appendix H) were also placed in clinics. For online recruitment, 
advertisements (Appendix I) were placed on consenting CFS/ME support group websites. 
Snowball sampling was facilitated whereby participants were able to share the online link via 
social media. Interested individuals were invited to complete an anonymous online survey via 
the Qualtrics platform. This included the participant information sheet (Appendix J), the 
consent form (Appendix K) and self-confirmation of having received a clinical diagnosis of 
CFS/ME (Appendix L).  Alternatively, paper surveys were made available upon request. 
Participants completed measures assessing demographic characteristics, fatigue, depression, 
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anxiety, and metacognitive beliefs and processes (Appendices L-Q). Upon completion of the 
measures and reading the electronic debriefing (Appendix R), each participant was given the 
option of entering a prize draw to potentially win one of ten £15 retail vouchers.  
Measures 
Descriptor Variables 
Demographic data, including age, gender and time since onset of CFS/ME symptoms, 
were collected using a questionnaire designed for this study (Appendix L). Due to overlap in 
symptoms and high prevalence of co-morbidities (Aaron et al., 2001;  Petersen et al., 2020) 
additional clinical information was gathered regarding the following self-confirmed 
diagnoses: depression, fibromyalgia, chronic pain syndrome and irritable bowel syndrome.  
Dependent Variable 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983; 
Appendices M & N) assessed depression, anxiety, and a composite score of emotional 
distress (HADS-t). The HADS comprises 14 statements about symptoms experienced during 
the past week. Each statement is scored on a 4-point scale (with anchor points of 0 = “not at 
all” to 3 = “very often”). Responses are summed to produce two subscale scores (anxiety and 
depression) and a composite score. The maximum total score for each subscale is 21. Severity 
is categorized as mild (8-10); moderate (11-14) and severe (15-21), (Stern, 2014). Caseness 
of both depression and anxiety in the present sample was defined by a score of eight or more 
(Olssøn et al., 2005). The HADS is widely used with physical health populations (Bjelland et 
al., 2002). The HADS demonstrates good internal consistency for patients with CFS/ME 
regarding the composite score (α = .87), depression (α = .79) and anxiety (α = .87), (McCue 
et al., 2006). High levels of internal consistency were indicated for this sample regarding the 
composite score (α = .92), depression (α = .85), and anxiety (α = .91).  
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Independent Variables 
The CFQ 11, an 11-item version of the Chalder Fatigue Scale (Cella & Chalder, 2010; 
Chalder et al., 1993; Appendix O) assessed fatigue severity. The shorter version of the scale 
was employed to reduce unnecessary participant burden. The CFQ-11 has two components 
(physical and mental fatigue). Questions relate to experiences of feeling tired, weak or 
lacking in energy during the past month. Responses can be scored on a 4-point Likert-scale 
(anchor points of 0 = “less than usual” to 3 = “much more than usual”), or bimodally (with 
columns scoring 0,0,1,1). Bimodal scoring effectively discriminates between CFS sufferers 
and the general population, with a score of 4 or more indicating clinical caseness (Cella & 
Chalder, 2010). Mean bimodal scores of 9.14 (SD 2.73) and 3.27 (SD 3.21) are reported for 
people living with CFS/ME and community samples respectively (Cella & Chalder, 2010). 
The CFQ 11 has good reliability CFS/ME patient groups (Morriss et al., 1998). Good internal 
consistency was indicated in this sample (α = .92) 
The Metacognitions Questionnaire-30 (MCQ-30; Wells & Cartwright-Hatton, 2004; 
Appendix P) assessed metacognitive beliefs. Subscales of the MCQ-30 measure five 
metacognitive belief domains: 1) positive beliefs about worry, measuring the perceived 
usefulness of perseverative thinking; 2) negative beliefs about the uncontrollability and 
danger of worry, measuring the extent to which perseverative thinking is experienced as 
uncontrollable and dangerous; 3) lack of cognitive confidence, measuring confidence in 
memory and attention; 4) the need to control thoughts, measuring beliefs that certain types of 
thought should be suppressed; and 5) cognitive self-consciousness, assessing tendencies 
towards thought monitoring and focusing attention inwards. Items are scored from 1 to 4 
(anchor points of 1 = “do not agree” to 4 = “agree very much”). The MCQ-30 demonstrates 
good internal consistency (α = .81 to α = .92) in patients with CFS/ME (Maher-Edwards et 
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al., 2011); the internal consistency for individual subscales in the current study ranged from 
α = .82 to α = .92. 
Mediator Variable 
The Cognitive Attentional Syndrome-10 (CAS-10; Wells, 2009; Appendix Q), a 10 
item self-report questionnaire, assessed the key aspects of the CAS (worry/rumination, threat 
monitoring and coping behaviours). Participants are asked to rate the degree to which they 
have used coping strategies including perseverative thinking during the previous week. 
Responses are scaled from 0%-100%. Items 1–6 assess perseverative thinking, threat 
monitoring (e.g. attentional focus on symptoms, thoughts and bodily checking) and unhelpful 
coping responses (e.g. avoidance and thought suppression). Items 7-10 duplicate items in the 
MCQ-30 and were therefore disregarded. Good levels of internal consistency were indicated 
in this sample (α = .87).  
 
Statistical Analysis 
Intercorrelations between predictor variables (age, fatigue, time since CFS onset, 
metacognitive beliefs and the CAS) were tested with parametric and non-parametric methods, 
as not all scales were normally distributed (Appendix S).  
Two multiple hierarchical regressions were used to test whether metacognitive beliefs 
explained a significant proportion of variance in anxiety (HADS-A) and depression (HADS-
D), after controlling for demographic and clinical variables, including level of fatigue. 
Multicollinearity and tolerance statistics were inspected for all variables (cut offs: variable 
inflation factor < 10, tolerance > 0.2, Belsley et al., 2005).   
 The order of entry into the regression was guided by methodological precedence, as 
well as the theory underpinning the hypotheses. Step one controlled for demographic 
variables (gender and age); Step 2 controlled for time since onset and co-morbidity with 
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listed health conditions; Step 3 controlled for level of fatigue; Step 4 controlled for the CAS; 
Step 5 controlled for metacognitive beliefs. Assumptions of linearity and homoscedasticity 
were assessed through examining probability plots and scatterplots (Appendix T). Histograms 
of standardized residual errors were inspected for normal distribution (Appendix T). Due to 
potential statistical discrepancies between original and log-transformed data (Feng et al., 
2014), bootstrapping with 5000 samples was used to adjust for bias and skewness in non-
normally distributed variables. Bias-corrected bootstraps give a robust estimation of 
confidence intervals. Cook’s distances were examined for influential cases.  
Mediation was used to test for direct and indirect effects of metacognitive beliefs on 
both depression and anxiety, as predicted by the S-REF model.  Four mediation analyses 
were conducted to test the hypothesized relationships between positive and negative 
metacognitive beliefs, the CAS, and the independent variables anxiety (HADS-A) and 
depression (HADS-D). The models examined whether the relationship between these 
metacognitive beliefs and depression/anxiety operated indirectly via the CAS. Clinical 
variables relevant to the hypotheses were controlled for, as were those making significant 
independent contributions in the final regression models. The following criteria were satisfied 
for conducting mediation analysis: all entered variables were significantly correlated; the 
models were based upon research indicating the potential role of metacognitive beliefs in 
causing emotional distress (Wells, 2013); and the associations between emotional distress and 
metacognitive beliefs were either eliminated or reduced when introducing the CAS (Kraemer 
et al., 2002). Analyses were completed using SPSS version 25 and the Hayes PROCESS 
macros (Hayes & Preacher, 2014). Bootstrapping with 5000 samples was used. 
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Power Calculation 
Assuming a medium effect size of .15, 95% power and an alpha of .05 to adjust for 
multiple regressions, power analysis indicated a minimum of 172 participants were required 
to power the most complex planned analysis – a multiple regression with 10 predictor 
variables (1) age; 2) time since initial onset of CFS/ME symptoms; 3) comorbidity with 
either: fibromyalgia, chronic pain syndrome or IBS;  4) symptom severity (level of fatigue); 
5) positive beliefs about worry; 6) negative beliefs about thoughts concerning 
uncontrollability and danger; 7) lack of cognitive confidence; 8) beliefs about the need to 
control thoughts; 9) cognitive self-consciousness; 10) the CAS. 
 
Results 
Sample Characteristics 
Table 1 displays sample characteristics. Of the total sample, 91.91% were female with 
a mean age of 43.78 years. Gender differences in key variables were examined using Mann 
Whitney and independent t-tests. No gender differences were found in respect of depression 
(t (233) = .744, p = .458), anxiety (t (233) = 1.891, p = .060), or fatigue (U = 2370, p = .261).   
Of the 235 participants, 220 met the clinical cut off for CFS/ME caseness using the 
CFQ-11 (Cella & Chalder, 2010). 163 participants reported mean levels of fatigue exceeding 
that reported for people with a CFS/ME diagnosis (Cella & Chalder, 2010). Common 
comorbid physical health conditions were reported by 151 participants (64.26 %) with the 
most common being IBS (43.40 %). There were statistically significant differences in mean 
HADS-D and HADS-A scores between participants who reported at least one listed physical 
co-morbidity, and those who did not (t (233) = 2.641, p = .009; t (233) = 5.508 , p < .001). In 
both cases, mean scores were higher in those reporting listed physical co-morbidities. Similar 
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differences were found in respect of the CAS (t (233) = 4.704, p < .001) and the MCQ-30 (t 
(233) = 5.174, p < .001).  
Clinically diagnosed depression was reported by 97 participants, (41.28%); however, 
HADS scores indicated 68.51% met the clinical threshold. HADS depression or anxiety 
casesness increased comorbidity of at least one listed condition or more to 186 participants 
(79.14%). The greatest proportion of depression cases were indicated to be mild-moderate 
(39.13 % and 36.65 % respectively). Nearly a quarter of cases (24.22 %) were indicated to be 
severe. The clinical threshold for anxiety was met by 155 participants (65.96%) with the 
greatest proportion of cases being moderate-severe (42.58% and 39.35 % respectively). The 
threshold for co-morbid depression and anxiety was met by 133 participants (56.60%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
 
Table 1.  
 
Sample Characteristics (N = 235) 
 
Variable  
 
N (%) or Mean (SD) 
Demographic variables 
 
 
Female 216 (91.91%) 
 
Male 19 (8.09%) 
 
Age in years  43.78 (SD 12.72) 
  
Clinical Variables 
 
 
Time since CFS/ME symptom onset (years) 13.22 (9.55) 
 
Self-reported dx of depression  97 (41.28%) 
 
Self-reported dx of fibromyalgia 83 (35.32%) 
 
Self-reported dx of chronic pain syndrome  45 (19.15%) 
 
Self-reported dx of irritable bowel syndrome 
 
102 (43.40 %)    
 
Self-reported dx of two or more listed physical health comorbidities  
 
151 (64.26 %) 
HADS comorbid Depression and Anxiety 133 (56.60%) 
 
HADS caseness for Depression ( > 8) 161 (68.51%) 
 
HADS caseness for Anxiety ( > 8) 155 (65.96%) 
 
HADS-D 
 
9.62 (SD 4.76) 
HADS-A 
 
10.31 (SD 5.99) 
HADS-t 
 
19.93 (SD 9.39) 
CFQ-11 10.00 (SD 2.37) 
Note: CF-S = Chalder Fatigue Scale; dx = diagnosis; HADS-A = Hospital Anxiety and Depression Scale, anxiety subscale; 
HADS-D = depression subscale; HADS-t = composite score of depression and anxiety.  
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Correlations and Descriptive Statistics 
Intercorrelations are displayed in Table 2. Consistent with hypothesis 1, CFQ-11 
scores were significantly positively correlated with HADS-A, HADS-D and HADS-t scores 
(r = .275 to .330, p < .001). Consistent with hypothesis 2, all MCQ30 subscales were 
significantly positively correlated with HADS-A, HADS-D and HADS-t scores (r =.312 to 
.813, p < .001) as well as CFQ-11 scores (r =.165, p = .011 to .432, p < .001). All MCQ30 
subscales were significantly positively correlated with CAS-10 scores (r =.442 to .732, p < 
.001). Significant positive correlations were found between CAS-10 and HADS-A, HADS-D 
and HADS-t scores (r =.643 to .773, p < .001). CFQ-11 and CAS-10 scores were moderately 
correlated (r =.311, p < .001). 
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Table 2. 
Intercorrelations Between Independent Variables, Mediator Variable and Depression and Anxiety  
 
 2 3 4 5 6 7 8 9 10 11 12 
1.Time Since Onset .349*** -.293*** -.132* -.087 -.204** -.146* -.150* -.070 -.197** -.150* .349*** 
2. Age  -.077 -.069 -.171** .063 -.177** -.226*** -.234*** 0.028 -.176** -.229*** 
3.Fatigue (CFQ-11)   .330*** .275*** .324*** .311*** .165 * .193 ** .432*** .190** .191** 
4.Distress (HADS-t)    .922*** .891*** .773*** .469*** .789*** .498*** .477*** .671*** 
5.Anxiety (HADS-A)      .646*** .751*** .512*** .813*** .409*** .530*** .679*** 
6.Depression (HADS-D)        .643*** .312*** .583*** .502*** .320*** .520*** 
7. Cognitive Attentional Syndrome (CAS-10)       .464*** .732*** .442*** .542*** .638*** 
8. Positive Metacognitive Beliefs (MCQ-30)        .446*** .222*** .455*** .532*** 
9. Negative Metacognitive Beliefs (MCQ-30)         .402*** .587*** .751*** 
10. Lack of Cognitive Confidence (MCQ-30)          .270** .332*** 
11. Cognitive Self-consciousness (MCQ-30)           .594*** 
12. Need to Control Thoughts (MCQ-30)            
Note: CAS-10 = Cognitive Attentional Syndrome Questionnaire (Wells, 2008); CFQ-11 = Chalder Fatigue Scale, 11 item version, (Cella & Chalder, 2010; Chalder et al., 1993); HADS-t = Total 
Distress (Hospital and Anxiety Scale, Zigmond & Snaith, 1983); HADS-A = Anxiety; HADS-D = Depression; MCQ-30 = Metacognitions Questionnaire-30 (Wells & Cartwright-Hatton, 2004) 
 
* p < 0.05; ** p < 0.01, *** p < 0.01 
 
Spearman’s correlations are italicized. 
 
67 
 
 
 
 
Metacognitive Beliefs, Depression and Anxiety 
 
Table 3 displays the hierarchical regression models examining the relationship 
between metacognitive beliefs and both anxiety and depression, whilst controlling for 
demographic and clinical variables. Inspection of histograms indicated normal distribution of 
standardized residuals. Plots indicated no evidence of heteroscedascity. Cook’s distances did 
not exceed one, indicating no undue influence exerted upon the regression models by a single 
case.  There was no evidence of multicollinearity (variance inflation factors < 5, tolerance 
statistics > 0.2). Variance inflation factors ranged between 1.032 and 3.326 and tolerance 
statistics ranged between .301 and .969.  
In the depression model, age (step 1) was non-significant (Fchange = .942, df =1,233 
p = .333). Entered at step 2, time since CFS/ME onset and comorbidity with at least one 
listed condition (Fibromyalgia/Chronic Pain/IBS) were statistically significant (Fchange = 
6.556, df = 2,231, p = .002), accounting for an additional 5.3% of the variance. Level of 
fatigue (step 3) and the CAS (step 4) were also statistically significant, (Fchange = 25.132, 
df = 1,230, p < .001; Fchange = 135.966, df = 1,229, p < .001), accounting for an additional 
9.3% and 31.7% of the variance in depression respectively. Consistent with hypothesis 3, 
metacognitive beliefs entered in the final step made a significant contribution (Fchange = 
8.152, df= 5,224, p < .001), accounting for an additional 8.2% of the variance. Overall, the 
model accounted for 54.9% of the variance in depression (R2 = .549, F (10, 224) = 27.263, p 
< .001). There were six independent predictors of depression in the final model; age (β = 
.206 p < 0.001); fatigue (β = .116 p = .025; the CAS (β = .372, p < .001); NMCB (β = .245, 
p = .003); LCC (β = .190, p < .001) and CSC (β = -.148. p < .013). 
In the model examining anxiety, demographic and clinical variables entered at each 
step were statistically significant. Age (step 1) accounted for 2.9% of the variance (Fchange 
= 6.995, df =1,233, p = .009). Time since CFS/ME onset and comorbidity with at least one 
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listed condition (step 2) accounted for an additional 11.7% of the variance (Fchange = 
15.771, df =2,231, p < .001). Fatigue (step 3) accounted for an additional 5.% of the 
variance (Fchange = 14.448 , df =1,230 p < .001). The CAS (step 4) accounted for an 
additional 38.7% of the variance (Fchange = 212.347, df = 1,229, p < .001). Consistent with 
hypothesis 3, metacognitive beliefs (step 5) made a significant contribution, accounting for 
an additional 14.5% of the variance in anxiety (Fchange = 23.760, df = 5,224, p < .001). 
Overall, the model predicted 72.7 % of the variance in anxiety (R2 = .727, F (10,224) = 
59.801, p < .001). In the final model, there were three independent predictors of anxiety; the 
CAS (β = .268, p < .001); PMCB (β = .169 p < .001); and NMCB (β = .520, p < .001); 
fatigue was not associated with anxiety (β = .075, p = .063).  
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Table 3 
 
Hierarchical Regression Models Predicting Depression and Anxiety. 
 
 
Depression  
 
Anxiety 
  
95% 
confidence 
intervals 
         
95% 
confidence 
intervals 
 
 Predictor R2 Adj R2 ΔR2 b SE β p LL UL  R2 Adj R2 ΔR2 b SE β p LL UL 
Step1                    
 Age    .024 .024 .063 .333 -.024 .072     -.075** .028 -.171** .009 -.131 -.019 
 .004 .000 .004    .333    .029 .025 .029    .009   
                    
Step 
2 
                    
 Age    .059 .027 .159 .026 .007 .112     -.025 .030 -.057 .402 -.084 .034 
 Onset     -.077 .035 -.154 .029 -.145 -.008     -.084 .039 -.144 .031 -.161 -.008 
 Other illness    1.924 .643 .194 .003 .656 3.191     3.802 .719 .327 <.001 2.386 5.218 
  .058 .045 .053    .003    .146 .135 .117    <.001   
                     
Step 
3 
                    
 Age    .058 .025 .154 .023 .008 .108     -.026 .029 -.060 .362 -.083 .031 
 Onset     -.033 .034 -.066 .340 -.100 .035     -.046 .039 -.079 .237 -.124 .031 
 Other illness    1.474 .619 .149 .018 .255 2.692     3.412 .706 .293 <.001 2.021 4.803 
 Fatigue    .262 .052 .320 <.001 .159 .364     .226 .060 .236 <.001 .109 .344 
  .150 .136 .093    <.001    .196 .182 .050    <.001   
                     
Step 
4 
    .071 .020 .189 <.001 .031 .110     -.010 .021 -.022 .648 -.051 .032 
 Age    .005 .027 .009 .867 -.049 .059     .002 .028 .004 .941 -.054 .058 
 Onset     -.049 .508 -.005 .924 -1.050 .952     1.438 .527 .124 .007 .398 2.477 
 Other illness    .128 .043 .157 .003 .043 .213     .053 .045 .056 .234 -.035 .141 
 Fatigue    .021 .002 .627 <.001 .018 .025     .028 .002 .693 <.001 .024 .031 
 CAS    .071 .020 .189 <.001 .031 .110  .583 .574 .387    <.001   
        <.001       -.010 .021 -.022 .648 -.051 .032 
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Table 3 
 
continued 
Depression  Anxiety 
         95% 
confidence 
intervals 
 
        95% 
confidence 
intervals 
 
 Predictor R2 Adj R2 ΔR2 b SE β p LL UL  R2 Adj R2 ΔR2 b SE β p LL UL 
Step 
5 
                    
 Age    .077 .019 .206 <.001 .039 .115     .024 .018 .054 .179 -.011 .058 
 Onset     -.009 .026 -.017 .740 -.059 .042     -.005 .023 -.009 .828 -.051 .041 
 Other llness    -.552 .481 -.056 .253 -1.50 .396     .623 .439 .054 .157 -.242 1.488 
 Fatigue    .095 .042 .116 .025 .012 .178     .072 .038 .075 .063 -.004 .147 
 CAS    .013 .002 .372 <.001 .008 .017     .011 .002 .268 <.001 .006 .015 
 PMCB    .098 .069 .081 .158 -.038 .234     .238 .063 .169 <.001 .114 .362 
 NMCB    .211 .070 .245 .003 .072 .350     .525 .064 .520 <.001 .399 .652 
 LCC    .169 .048 .190 <.001 .075 .264     .013 .044 .013 .763 -.073 .099 
 CSC    -.163 .065 -.148 .013 -.292 -.034     -.011 .060 -.009 .853 -.129 .107 
 NCT    .108 .084 .097 .199 -.058 .274     -.017 .077 -.013 .821 -.169 .134 
  .549 .529 .082    <.001    .727 .715 .145    <.001   
 
Note: Adj R2 = adjusted R2 ; CAS = cognitive attentional syndrome; CSC = cognitive self-consciousness LCC = lack of cognitive confidence; LL = lower limit; NCT = need to control thoughts; NMCB = negative 
metacognitive beliefs; Onset = time since CFS/ME onset; PMCB = positive metacognitive beliefs; SE = standard error; UL = upper limit.   
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Mediation Analyses 
 
The model which assessed the role of the CAS in mediating the relationship between 
PMCBs and depression (fig 2) indicated full mediation; the direct effect between PMCBs and 
depression was no longer significant, when accounting for the CAS (b = .097, t (226) = 
1.404, p = .162).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model which assessed the role of the CAS in mediating the relationship between NMCBs 
and depression (fig 2) indicated partial mediation; the direct effect between NMCBs and 
depression remained significant, when accounting for the CAS (b = .199, t (226) = 2.850, p = 
.005).  
 
Note: BCa =  bias-corrected and accelerated bootstrap;  CAS = 
cognitive attentional syndrome; PMCBs = positive metacognitive 
beliefs.  
Model covariates: age; fatigue; negative metacognitive beliefs; 
cognitive self-consciousness; lack of cognitive confidence; beliefs 
about the need to control thoughts. 
Bootstrapping with 5000 samples. 
* = p < .05; *** = p <.001 
Fig. 1. 
 
 Mediation of Association Between PMCBs and Depression via the CAS. 
 
CAS 
Depression 
b = .013*** 
 
 
b = 3.960* 
 
b = .097,  
    (b = .146*) 
a b 
c’ (c) 
Indirect effect = .050, BCa 95% CIs = .006 to .104 
PMCBs 
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The model which assessed the role of the CAS in mediating the relationship between PMCBs 
and anxiety (fig.3) indicated partial mediation; the direct effect between PMCBs and anxiety 
remained significant, when accounting for the CAS (b = .238, t (226) = 3.781 , p < .001). The 
model which assessed the role of the CAS in mediating the relationship between NMCBs and 
anxiety (fig. 4) indicated partial mediation; the direct effect between NMCBs and anxiety 
remained significant, when accounting for the CAS (b = .537 p < .001).  
 
 
 
Note: BCa =  bias-corrected and accelerated bootstrap; CAS = 
cognitive attentional syndrome; NMCBs = negative metacognitive 
beliefs.  
Model covariates: age; fatigue; positive metacognitive beliefs; 
cognitive self-consciousness; lack of cognitive confidence; beliefs 
about the need to control thoughts. 
 Bootstrapping with 5000 samples. 
** = p <.01; *** = p < .001. 
b 
Fig. 2.  
 
Mediation of Association Between NMCBs and Depression via the CAS. 
 
 
. 
 
CAS 
Depression 
b = .013***     b = 12.862*** 
b = .199**  
(b = .360)***    
Indirect effect = .161, BCa 95% CIs = .085 - .253 
a 
c’ (c) 
NMCBs 
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Note: BCa =  bias-corrected and accelerated bootstrap; CAS = cognitive 
attentional syndrome; PMCBs = positive metacognitive beliefs.  
Model covariates: age; fatigue; negative metacognitive beliefs; cognitive 
self-consciousness; lack of cognitive confidence; beliefs about the need to 
control thoughts. 
Bootstrapping with 5000 samples. 
* = p < .05; *** = p < .001; 
a b 
Note: BCa = bias-corrected and accelerated bootstrap; CAS = cognitive 
attentional syndrome; NMCBs = negative metacognitive beliefs. 
Model covariates: age; fatigue; positive metacognitive beliefs; cognitive 
self-consciousness; lack of cognitive confidence; beliefs about the need to 
control thoughts. 
Bootstrapping with 5000 samples. 
*** = p < .001. 
Fig. 3. 
 
Mediation of Association Between PMCBs and Anxiety via the CAS. 
 
 
. 
 
Fig. 4.  
 
Mediation of Association Between NMCBs and Anxiety via the CAS. 
 
 
CAS 
Anxiety 
b = .011*** b = 3.960* 
 
b = .238*** 
(b = .281***) 
Indirect effect = .043, BCa 95% CIs = .003- .095  
a b 
c’ (c) 
PMCBs 
CAS 
NMCBs Anxiety 
b = .011*** b = 12.862*** 
b = .537*** 
  (b = .677***) 
) 
Indirect effect = .139, BCa 95% CIs = .068 - .223 
c’ (c) 
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Discussion 
Consistent with existing evidence (Fischler et al., 1997; Fuller-Thomson & Nimigon, 
2008; Iwase et al., 2008; White et al., 2011), higher levels of depression and anxiety were 
reported in this sample, compared to the general population (McManus, et al., 2016). Both 
metacognitive beliefs and the CAS were significantly and positively associated with both 
depression and anxiety; analyses indicated moderate-strong associations. When controlling 
for demographic and clinical variables including fatigue, metacognitive beliefs accounted for 
an additional 8.2% and 14.5% of the variance in depression and anxiety respectively. 
Consistent with hypothesis 4, the CAS fully mediated the relationship between positive 
metacognitive beliefs and depression; partial mediation by the CAS was indicated for the 
relationships between positive metacognitive beliefs and anxiety, and between negative 
metacognitive beliefs and both depression and anxiety. These findings are consistent with 
previous research examining the utility of the S-REF model in physical health populations 
(Cook et al., 2015; Heffer-Rahn & Fisher, 2018) and the underlying theory.  
 
Implications for theory  
The S-REF model proposes that beliefs about the usefulness of worry and rumination 
lead both directly and indirectly to anxiety and depression. Operating at a low level of 
conscious awareness, these PMCBs activate perseverative thought processes, threat-focussed 
attention, and maladaptive cognitive and behavioural coping strategies. Together these 
processes form the CAS. In the case of anxiety, perseverative thinking is characterized by 
worry and in the case of depression, by rumination. According to the S-REF model, these 
strategies backfire, as NMCBs cause worry/rumination to be perceived as uncontrollable and 
dangerous. 
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Differential outcomes for anxiety and depression in this study are broadly consistent 
with the S-REF model. Both positive and negative metacognitive beliefs are implicated in the 
metacognitive model of Generalized Anxiety Disorder (GAD, Wells, 2009); in response to a 
trigger, PMCBS activate the selection of worry as a strategy, which in turn activates NMCBs 
about the uncontrollability and danger of worry and subsequently, the CAS. This is reflected 
in the final regression model, where the three independent statistical predictors of anxiety 
were both positive and negative metacognitive beliefs and the CAS.  
The metacognitive model of depression proposes PMCBs activate depressive 
rumination as a strategy to overcome problems, including depression itself. This in turn 
activates NMCBs about the uncontrollability of rumination. Although PMCBs did not make 
as an independent contribution to depression in the final regression model (β = .081, p = 
.158), the CAS fully mediated the association between PMCBs and depression; findings 
suggest it is not the PMCB which underpin selection of rumination as a strategy which is 
significant, but rather depressive rumination itself, which is a central feature of the CAS 
(Wells, 2009). Findings from the regression analysis corroborate the centrality of NMCBs 
and the CAS, as outlined in the metacognitive model of depression.  
The S-REF model (Wells & Matthews 1994) proposes that higher levels of cognitive 
self-consciousness (CSC) will be associated with more severe depression. However, in the 
present study, higher CSC was associated with lower levels of depression. A comparable find 
was obtained when examining metacognitive beliefs and depression in people living with 
multiple sclerosis (Heffer-Rahn & Fisher, 2018). The negative association between cognitive 
self-consciousness and depression may reflect an avoidance strategy which limits distress in 
the short term but is counterproductive in the longer term.  More specifically, people are 
monitoring their minds for the presence of negative thoughts but are using a range of 
suppression strategies to remove those thoughts as rapidly as possible.  If suppression 
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strategies no longer remove the thoughts then it is possible that this will activate NMCBs 
thereby increasing distress (Palmier‐Claus et al., 2013; Wells, 1997).  The positive 
association between LCC and depression is consistent with predictions of the S-REF model 
(Wells & Matthews 1994); LCC may be a consequence of depressive rumination, which 
further perpetuates depression (Papageorgiou & Wells, 2003). Specifically, perseverative 
negative thinking may detract from other aspects of cognition, thereby reducing confidence in 
one’s own memory, concentration and attention.  
 
Study Limitations 
This study offers preliminary evidence that both metacognitive beliefs and the CAS 
contribute to co-morbid depression and anxiety in CFS/ME. However, conclusions must be 
drawn with caution, given the cross-sectional nature of the research. This is arguably a 
particular concern in mediation analysis (Wiederman & von Eye., 2015), whereby the 
causality could be reversed or indeed bi-directional. As well as contributing to depression and 
anxiety, the strength of metacognitive beliefs could fluctuate in response to varying levels of 
depression and / or anxiety. Such dynamic relationships may be mediated by the CAS. 
Nevertheless, predictions were based upon empirical evidence. This initial study provides a 
basis for further longitudinal research to corroborate directions of causality.  
Despite recruitment from three specialist clinics, this represented only 6.8% of 
respondents. This is hypothesized to reflect at least in part, comparative ease of accessibility 
via the advertisement online. Nevertheless, the study sought to recruit a large, representative 
sample including both those open to specialist CFS/ME services, and those who were not. 
Two million adults living with CFS/ME in the UK are unable to access specialist services 
(Collin, Sterne, Hollingworth, May, & Crawley, 2012). Furthermore, due to the nature and 
duration of the illness, patients are likely to be discharged following non-curative, time-
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limited interventions, whilst still experiencing symptoms to some degree. Recruitment from 
online support groups offers this population opportunity to engage with research.  
Whilst self-confirmation of a clinical diagnosis was a requirement for participation, 
confirmation from a health professional would have increased methodological rigour. 
Nevertheless, such increased stringency was beyond the scope of this study and may have 
impacted upon the representativeness of the sample. Furthermore, the likelihood of a reduced 
sample size would have had implications for statistical power. Most participants (93.6%) 
exceeded the CFQ-11 cut off scores for clinical caseness; scores not meeting this threshold 
may be attributable to fluctuations in symptom severity across the course of the illness and 
possible progress towards recovery.  
In order to minimise participant burden, measures of secondary symptoms were not 
included. It was therefore not possible to statistically control for cognitive symptoms such as 
difficulties with short-term memory, attention and concentration (Carruthers et al., 2011), 
which may overlap or interact with LCC. There is likely to be a dynamic relationship 
between the cognitive symptoms themselves and reduced personal confidence in these 
abilities (LCC). This may be mediated by factors such as anxiety. For example, experiencing 
difficulties in concentration may lead to anxiety about one’s ability to concentrate, which 
may reduce confidence in this ability. Furthermore, this may drive worry and rumination, 
potentially further reducing the cognitive capacity for concentration.  Future studies may 
therefore consider broader symptom measures or subscales (Jason et al., 2015; Sunnquist et 
al., 2019) to facilitate more complex statistical analysis.   
Despite the selection of shortened versions of psychometric measures in this study, 
those most severely affected are less likely to take part in research due to the impact of their 
symptoms (Strassheim et al., 2018). Similarly, correspondence was received by the authors 
indicating a proportion of the CFS/ME population reject the relevance of psychological 
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research; this suggests a further sub-group who are likely to be un-represented. These are 
nevertheless broader issues in CFS/ME research, rather than this study per se.  
	
Clinical implications 
The S-REF model provides a theoretical basis for understanding comorbid depression 
and anxiety in CFS/ME. When controlling for relevant demographic and clinical variables 
including level of fatigue, metacognitive beliefs accounted for additional variance in 
depression and anxiety. The relationship between positive and negative metacognitive beliefs 
operated indirectly through the CAS. Translated into clinical practice, this indicates the 
potential therapeutic benefits of counteracting perseverative thinking, attentional focus, and 
unproductive coping strategies, as well as the metacognitive beliefs which underpin their 
selection and continuation. Metacognitive therapy (Wells, 2009) may be effective in 
modifying metacognitive beliefs and the CAS 
Longitudinal research is required to examine whether metacognitive beliefs are 
vulnerability markers for persistent anxiety and depression in CFS/ME.  Early identification 
of metacognitive beliefs, perseverative thought processes and coping strategies could reduce 
the emotional distress experience by people with CFS/ME.  
 
Conclusion 
MCT may be effective in reducing co-morbid depression and anxiety in people living 
with CFS/ME. In targeting metacognitive processes which maintain distress, as opposed to 
questioning the validity of illness-related cognitions, MCT may be acceptable to this patient 
group. Within the context of controversy surrounding the role of psychological approaches, 
MCT has the potential to offer an efficacious psychological intervention, as part of a living 
well with chronic illness approach.  
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Appendix A: Extracts from Author Guidelines for the Journal of Psychosomatic 
Research  
 
Review Articles 
Review papers are normally systematic reviews following the PRISMA statement of 4000-
5000 words (Introduction through Discussion). 
 
NEW SUBMISSIONS 
Formatting requirements 
There are no strict formatting requirements but all manuscripts must contain the essential 
elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, 
Materials and Methods, Results, Conclusions, Artwork and Tables with Captions. 
If your article includes any Videos and/or other Supplementary material, this should be 
included in your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text 
Figures and the tables included in the single file can be placed next to the relevant text in the 
manuscript or at the bottom of the file. The corresponding caption should be placed directly 
below the figure or table. 
References 
There are no strict requirements on reference formatting with new submissions. References 
can be in any style or format as long as the style is consistent. Where applicable, author(s) 
name(s), journal title/book title, chapter title/article title, year of publication, volume 
number/book chapter and the article number or pagination must be present. Use of DOI is 
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highly encouraged. Revisions should be submitted in the Journal of Psychosomatic 
Research format as the reference style used by the journal will be applied to the accepted 
article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage 
for the author to correct. 
Submissions 
Manuscripts should conform to the uniform requirements known as the 'Vancouver style' 
(International Committee of Medical Journal Editors. Uniform requirements for manuscripts 
submitted to biomedical journals. N Engl J Med 1997; 336:309-315). 
Reference style 
Text: Indicate references by number(s) in square brackets in line with the text. The actual 
authors can be referred to, but the reference number(s) must always be given. 
List: Number the references (numbers in square brackets) in the list in the order in which they 
appear in the text. 
Revised submissions 
Title Page This should contain (a) the title of the article; (b) a short running head; (c) name of 
department where the work was conducted; (d) names of each author with highest academic 
degree; (e) name, address, phone and fax of author responsible for correspondence and to 
whom requests for reprints should be addressed. Structured Abstract This should be 
subdivided under the headings Objective, Methods, Results, and Conclusion and should not 
exceed 250 words. Be sure that key information, such as study design and sample size are 
included. For primary results, include some measure of the magnitude of the association and 
not simply a p-value. Keywords Up to six keywords should be listed in alphabetical order 
after the abstract. These terms should optimally characterize the paper to facilitate choice of 
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peer reviewers. Article Structure The text should be divided into sections with main 
headings: Introduction, Method, Results and Discussion and, in total, these sections should 
not normally be greater than 4000 words in length. Acknowledgements Collate 
acknowledgements in a separate section at the end of the article before the references and do 
not, therefore, include them on the title page, as a footnote to the title or otherwise. 
Acknowledgements must include mention of any source of funding outside the basic funding 
of the host institution (see Role of the funding source above). List here those individuals who 
provided help during the research (e.g., providing language help, writing assistance or proof 
reading the article, etc.). Tables Number tables consecutively in accordance with their 
appearance in the text. Place footnotes to tables below the table body and indicate them with 
superscript lowercase letters. Any abbreviations used should be included in the footnotes with 
enough information for the reader to understand without referring back to the text. Avoid 
vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do 
not duplicate results described elsewhere in the article. Figures Each should be on a separate 
sheet, and numbered consecutively. Captions should be on a separate sheet. Any 
abbreviations used should be included in the captions with enough of a description for the 
figures to be interpreted independently from the text. The number of illustrations should be 
kept to a minimum. Colour illustrations are not normally acceptable. Authors may be asked 
to support the costs of colour reproduction. 
 
Abbreviations  
Keep abbreviations to a minimum and avoid their use in the abstract. Spell out each 
abbreviation in the text the first time that it is used. Ensure consistency of abbreviations 
throughout the article. 
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Footnotes  
Footnotes should be used sparingly. Number them consecutively throughout the article. Many 
word processors build footnotes into the text, and this feature may be used. Should this not be 
the case, indicate the position of footnotes in the text and present the footnotes themselves 
separately at the end of the article. 
 
References 
 These should be numbered consecutively in the text in the order in which they are first 
mentioned and be so denoted in the list. Their form should be that adopted by the US 
National Library of Medicine, as used in the Index Medicus and as recommended in Huth EJ, 
Medical Style and Format. Reference links Increased discoverability of research and high 
quality peer review are ensured by online links to the sources cited. In order to allow us to 
create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, 
please ensure that data provided in the references are correct. Please note that incorrect 
surnames, journal/book titles, publication year and pagination may prevent link creation. 
When copying references, please be careful as they may already contain errors. Use of the 
DOI is highly encouraged. 
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Appendix B: Extract from British Journal of Health Psychology 
 MANUSCRIPT CATEGORIES AND REQUIREMENTS 
Papers describing quantitative research (including reviews with quantitative analyses) should 
be no more than 5000 words (excluding the abstract, reference list, tables and figures).  
PREPARING THE SUBMISSION 
Free Format Submission 
British Journal of Health Psychology now offers free format submission for a simplified and 
streamlined submission process. 
Before you submit, you will need: 
• Your manuscript: this can be a single file including text, figures, and tables, or 
separate files – whichever you prefer. All required sections should be contained in 
your manuscript, including abstract, introduction, methods, results, and conclusions. 
Figures and tables should have legends. References may be submitted in any style or 
format, as long as it is consistent throughout the manuscript. If the manuscript, figures 
or tables are difficult for you to read, they will also be difficult for the editors and 
reviewers. If your manuscript is difficult to read, the editorial office may send it back 
to you for revision. 
• The title page of the manuscript, including a data availability statement and your co-
author details with affiliations.  
The title page should contain: 
• A short informative title containing the major key words. The title should not contain 
abbreviations  
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• A short running title of less than 40 characters 
• The full names of the authors 
• The author's institutional affiliations where the work was conducted, with a footnote 
for the author’s present address if different from where the work was conducted 
• Abstract 
• Keywords 
• Data availability statement (see Data Sharing and Data Accessibility Policy); 
• Acknowledgments. 
Abstract 
For articles containing original scientific research, a structured abstract of up to 250 words 
should be included with the headings: Objectives, Design, Methods, Results, Conclusions.   
 
Revised submissions 
References 
References should be prepared according to the Publication Manual of the American 
Psychological Association (6th edition). This means in text citations should follow the 
author-date method whereby the author's last name and the year of publication for the source 
should appear in the text, for example, (Jones, 1998). The complete reference list should 
appear alphabetically by name at the end of the paper. Please note that for journal articles, 
issue numbers are not included unless each issue in the volume begins with page 1, and a 
DOI should be provided for all references where available. 
Tables 
Tables should be self-contained and complement, not duplicate, information contained in the 
text. They should be supplied as editable files, not pasted as images. Legends should be 
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concise but comprehensive – the table, legend, and footnotes must be understandable without 
reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, 
§, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical 
measures such as SD or SEM should be identified in the headings. 
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Appendix C: Quality Assessment Tool – Adapted from Williams et al., (2010) 
General instructions: Grade each criterion as “Yes,” “No,” “Partially,” or “Can’t tell.” 
Factors to consider when making an assessment are listed under each criterion. Criteria 
marked italics are considered the most essential quality indicators for our purposes. 
1. Unbiased selection of the cohort? 
Factors that help reduce selection bias: 
o Inclusion/exclusion criteria 
§ Clearly described diagnostic criteria for CFS/ME and/ or additional 
assessments e.g. psychiatric assessment, assessment by a physician, 
biological tests to rule out other causes of physical symptoms 
§ Assessed using valid and reliable measures of fatigue / physical 
symptoms. 
o Recruitment strategy 
§ Clearly described 
§ Relatively free from bias (selection bias might be introduced, e.g., by 
recruitment via advertisement; at a particular stage in diagnosis / 
treatment; consecutively admitted patients) 
2. Sample size calculated/5% difference? 
Factors to consider: 
o Did the authors report conducting a power analysis or describe some other 
basis for determining the adequacy of study group sizes for the primary 
outcome(s) of interest to us? 
o Was the sample size sufficiently large to detect a clinically significant 
difference of 5% in event rates or an OR/RR increase of ≥ 1.5 or decrease of ≥ 
0.67 between groups in at least one primary outcome measure of interest to 
us? 
3. Adequate description of the cohort? 
Consider whether the cohort is well-characterized in terms of baseline: 
o Age 
o Sex 
o Race 
o Educational level 
o Time since CFS/ME symptom onset 
o Mean level of fatigue 
o Mean level of anxiety and depression / clinical caseness  
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o Level of cognitive symptoms 
 
4. Validated measures of depression / anxiety / perfectionism? 
Factors to consider: 
o Were the psychometric measures clearly described and referenced? 
o Were validated psychometric measures used?   
 
5. Analysis controls for confounding? 
Factors to consider: 
o Does the study identify and control for important confounding variables e.g. 
level of cognitive symptoms, time since CFS/ME onset.  
6. Analytic methods appropriate? 
Factors to consider: 
o Was the kind of analysis done appropriate for the kind of outcome data? 
o Was the number of variables used in the analysis appropriate for the sample 
size? (The statistical techniques used must be appropriate to the data and take 
into account issues such as controlling for small sample size, clustering, rare 
outcomes, multiple comparison, and number of covariates for a given sample 
size.  
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submission to REC and any other regulatory authorities (as per SOP018); 
 
It is a requirement that Annual Progress Reports are sent to the NHS Research Ethics Committee (REC) annually 
following the date of Favourable Ethical Approval. You must provide copies of any reports submitted to REC and other 
regulatory authorities to the Research Support Office; 
 
Maintain the study master file (as per SOP005); 
 
Make available for review any study documentation when requested by the sponsors and regulatory authorities for the 
purposes of audit or inspection; 
 
Upon the completion of the study it is a requirement to submit an End of Study Declaration (within 90 days of the end of 
the study) and End of Study Report to REC (within 12 months of the end of the study). You must provide copies of this to 
the Research Support Office; 
 
Ensure you and your study team are up to date with the current RSO SOPs throughout the duration of the study. 
 
If you have any queries regarding the sponsorship of the study, please do not hesitate to contact the Clinical Research 
Governance Team on 0151 794 8373 (email sponsor@liverpool.ac.uk). 
 
Yours sincerely, 
 
Miss Lara Lavelle-Langham 
Research Integrity and Governance 
Manager Research Support Office 
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Dr Peter Fisher 
University of Liverpool 
Wheelan Building, The Quadrangle 
Brownlow Hill, Liverpool 
L69 3GB 
 
Email: hra.approval@nhs.net 
Research-permissions@wales.nhs.uk 
 
30 May 2019 
 
Dear Dr Fisher 
 
 
 
Study title: Are metacognitive processes associated with distress 
in people with chronic fatigue symptoms? 
IRAS project ID: 253333 
Protocol number: UoL001442 - 4246 
REC reference: 19/NW/0406 
Sponsor University of Liverpool 
 
Thank you for your application for HRA and Health and Care Research Wales 
(HCRW) Approval. I am writing to confirm that you are now able to share the Local 
Information Pack with participating NHS organisations in England and Wales in order 
to invite them to arrange of capacity and capability to deliver your study. Please note 
that the research should not begin at any participating NHS organisations in 
England or Wales until HRA and HCRW Approval is issued. 
 
To share the Local Information Pack with participating NHS organisations in 
England and Wales please use the template email available on the IRAS website. 
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Once the Local Information Pack has been shared, please work with participating 
NHS organisations to arrange capacity and capability, in line with the instructions 
provided in the 
 “Information to support study set up” section towards the end of this letter. 
What happens next with my application for HRA and HCRW Approval? 
 
 
Page 1 of 4 
 
 
Your application is progressing. Please find below an indication of where you are 
in the process (indicated by the red box). 
 
 
 
I am undertaking the assessment of the application and you will receive any queries 
following the REC meeting. 
 
How should I work with participating NHS/HSC organisations in Northern 
Ireland and Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations in Northern 
Ireland and Scotland. 
 
If you indicated in your IRAS form that you have participating organisations in 
Northern Ireland and/or Scotland, the national coordinating function of each 
participating nation has been informed and provided with the initial document set. The 
relevant national coordinating function/s will contact you as appropriate. We will 
provide them the final document set and study wide governance report when 
available. 
 
Please see IRAS Help for information on working with NHS/HSC organisations in 
Northern Ireland and Scotland. 
 
How should I work with participating non-NHS organisations? 
253333 IRAS 
project ID 
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HRA and HCRW Approval does not apply to non-NHS organisations. You should 
work with your non-NHS organisations to obtain local agreement in accordance with 
their procedures. 
 
 
 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. My contact details 
are below. 
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Your IRAS project ID is 253333. Please quote this on all correspondence 
 
Yours sincerely, 
 
Isobel Lyle 
HRA Approvals Manager 
Health Research Authority 
NHSBT Newcastle Blood Donor Centre | Holland Drive | HRA Newcastle | NE2 4NQ 
T. 0207 972 2496 
E. isobel.lyle@nhs.net 
W. www.hra.nhs.uk 
 
Copy to: Mr Alex Astor 
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Information to support study set up 
 
The below provides all parties with information to support the arranging of capacity and capability with participating NHS organisations in England 
and Wales. This is intended to be an accurate reflection of the study at the time of issue of this letter. As part of the application process, details 
may change prior to a Letter of HRA and HCRW Approval being issued. 
Types of 
participating 
NHS 
organisation 
Expectations related to 
confirmation of 
capacity and capability 
Agreement to be 
used 
Funding 
arrangements 
Oversight 
expectations 
HR Good Practice Resource 
Pack expectations 
There is one site 
type where all 
site activities will 
be undertaken. 
Research activities 
should not commence at 
participating NHS 
organisations in England 
or Wales prior to their 
formal confirmation of 
capacity and capability 
to deliver the study. 
A statement of 
activities has been 
submitted and the 
sponsor is not 
requesting and 
does not expect 
any other site 
agreement to be 
used. 
No application for 
funding is being 
made. Details of 
resource materials 
being made 
available to sites 
are included in the 
Statement of 
Activities 
A Local 
Collaborator is 
required at each 
site and named 
LC’s are in place 
It is unlikely that letters of 
access or honorary research 
contracts will be applicable, 
however, for research team 
members only administering 
questionnaires or surveys, a 
Letter of Access based on 
standard DBS checks and 
occupational health clearance 
would be appropriate, if 
required. 
 
Other information to aid study set-up and delivery 
 
This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up. 
The applicant has indicated that they intend to apply for inclusion on the NIHR CRN Portfolio 
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Consent to Contact Form 
 
 
 
 
 
 
We are currently completing research into ME / CFS in conjunction with 
the University of Liverpool 
If you are between 18 and 75 and you may be interested in participating, 
please complete this form and return it to your clinician / clinic 
administration staff to receive further information. 
 
 
 
 
Please select one of the following:  
 
I would prefer to receive: 
 
☐ A paper advertisement with a web link to further information and an online survey. 
 
☐ A participant information sheet and a paper survey.  
 
 
 
 
I consent to receiving further written information regarding this research. 
 
 
Signed: ……………………………………….    date:…………. 
 
Print:     ………………………………………. 
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      Appendix I: Online Advertisement 
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PARTICIPANT INFORMATION SHEET 
 
Emotional Distress and Chronic Fatigue Symptoms 
 
Project Research Ethics Number: 253 333 
 
We are inviting you to participate in a research study. Before you decide whether to 
participate, it is important for you to understand why the research is being done and 
what it involves. Please take time to read the following information carefully and feel 
free to ask if you would like more information or if there is anything that you do not 
understand. Please also feel free to discuss this with your friends, relatives and your 
GP. You do not have to accept this invitation and should only agree to take part if you 
want to. 
 
What is the purpose of this study? 
We are interested in factors associated with emotional distress in people living with 
chronic fatigue symptoms (PWCFS). These symptoms are experienced by people with 
diagnoses including Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME), 
and Chronic fatigue and immune dysfunction syndrome (CFIDS).  
 
Why is this research needed? 
Emotional distress can be a common experience for people living with chronic fatigue 
symptoms. However, little is known about the factors associated with emotional distress.  
This means it is difficult to develop therapeutic interventions for emotional distress which 
may be experienced by people living with chronic fatigue symptoms. 
 
Appendix J: Participant Information Sheet 
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Why have I been asked to take part? 
The invitation to take part in the study does not mean that we think you have problems 
with emotional distress. We are inviting people to participate regardless of how they 
presently feel  
The study aims to include at least 118 people between the ages of 18 and 75, who have 
received a clinical diagnosis of either Chronic Fatigue Syndrome (CFS), Myalgic 
Encephalomyelitis (ME) or Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS).  
 
Do I have to take part? 
No. It is up to you whether you agree to take part. If you do decide to take part, you 
will be asked to sign a consent form.  
 
What will happen if I agree to take part? 
You will be asked to complete a survey which will take around 20-30 minutes. You 
will be asked to complete this within two hours and can take breaks during if you need to do 
so. The online version of the survey has an option to save and continue. 
You will be asked a series of questions about you (e.g. age/gender) and your 
symptoms (e.g. fatigue, low mood, worry. You will not be asked to identify yourself as an 
individual.  
 
How will my data be used?  
The University of Liverpool is the sponsor for this study based in the United 
Kingdom. The University will be using information from you in order to undertake this 
study. The University is responsible for looking after your information and using it properly. 
 Under UK data protection legislation, the University acts as the Data Controller for personal 
data collected as part of the University’s research. The Principal Investigator acts as the Data 
Processor for this study, and any queries relating to the handling of your personal data can be 
sent to peter.fisher@liverpool.ac.uk  
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The University processes personal data as part of its research and teaching activities in 
accordance with the lawful basis of ‘public task’, and in accordance with the University’s 
purpose of “advancing education, learning and research for the public benefit.” 
 
Further information on how your data will be used can be found in the table below: 
 
 
 
How will my data be collected? 
 
Data will be collected through 
either an online or paper survey.  
 
How will my data be stored? 
 
Data from the online surveys will 
be stored on the Qualtrics server 
for a maximum of one week, 
before being transferred to a 
database on the University of 
Liverpool Secure Server. 
 
Data from paper surveys will be 
entered onto the same database on 
at least a monthly basis. Following 
this, they will be destroyed 
immediately. 
 
Paper surveys submitted to NHS 
clinics will be held securely until 
they are collected by the 
researcher. 
  
 
How long will my data be stored 
for?  
 
Data collected in this study may 
be held for up to 10 years. 
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What measures are in place to 
protect the security and 
confidentiality of my data? 
 
Qualtrics stores data on a secure 
European Union server (which is a 
legal requirement for data collected 
from EU citizens).The only people 
who will have access to the data is 
the Researcher and the Primary 
Investigator. 
 
The University of Liverpool has a 
specific contract with Qualtrics. 
 
For the duration of the study, a 
database storing survey data and 
email addresses for the prize draw 
will be kept securely a University 
of Liverpool server. 
 
Email addresses will be used solely 
for the purposes of the prize draw 
or feedback on the outcome of the 
research if requested. Email 
addresses will be separated from 
survey data and stored on a 
password protected computer 
system, accessible to the 
Researchers only. They will be 
destroyed when they are no longer 
needed. 
 
 
Will my data be anonymised? 
 
Your data will be anonymous at 
the point of collection. 
Email addresses will not be linked 
to the data you submit when 
entered into the database. You will 
not be identifiable as an individual 
when we gather, analyse the data 
or write reports about the study. 
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How will my data be used? 
 
 
Once the study is complete, we 
will analyse the results and publish 
it in academic journals. We will 
not identify you in any way when 
the results are published.  Should 
you so wish, we will send you a 
short report of the findings of the 
study. 
 
 
Who will have access to my data? 
 
 
Information will not be revealed to 
anyone outside of the research 
team. 
 
Will my data be archived for use 
in other research projects in the 
future? 
 
 
No 
 
How will my data be destroyed? 
 
Data from paper surveys will be 
shredded immediately following 
entry to the secure database. 
 
The database will be deleted no 
later than ten years after 
completion of the study. 
 
 
 
Expenses and / or payments  
There are no payments for taking part. However, to thank participants for taking part 
we are offering the chance to enter a prize draw for one of ten £15 retail vouchers. Winners 
will be selected from random via computer software. Details will be given to those who have 
completed the surveys.    
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Are there any risks in taking part? 
 
There are no known risks of taking part and the survey consists of surveys completed 
by lots of people living with chronic fatigue symptoms. However, some of the questions ask 
about negative emotions and symptoms which can be upsetting. You are under no obligation 
to complete the survey and can stop at any time.  
If you become fatigued whist completing the survey over 20-30 minutes, there is an 
option to save your responses and continue when you are rested.  
If completing the survey raises any concerns, there are several options to obtain further 
advice outlined below: 
 
1) You could talk to your GP to discuss your concerns. 
2) There several websites and organizations which provide information and advice about 
Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis (ME). These include: 
 
• Action for ME ( https://www.actionforme.org.uk )  
          Telephone: 0117 927 9551  
 
• The ME Association www.meassociation.org.uk  
Telephone: 0344 576 5326 
 
3) 3) The NHS website https://www.nhs.uk/conditions/chronic-fatigue-syndrome-
cfs/treatment/ also offers advice. 
 
4) If completing the survey causes any discomfort, you can contact the Principal 
investigator Dr Peter Fisher, Senior Lecturer in Clinical Psychology: 
Email: peter.fisher@liverpool.ac.uk 
Telephone: 0151 794 4160 
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What are the possible benefits of taking part? 
There are no immediate personal benefits.  However, the data obtained from the 
survey may help to improve psychological treatments for PWCFS experiencing emotional 
distress. 
 
What will happen to the results of the study? 
The data obtained from the survey will be analysed and may be published in an 
academic journal. The results will also be written up as part of a thesis being conducted by a 
Clinical Psychology student.  The write up of the study will not contain any information 
which could identify you. 
 
What will happen if I want to stop taking part? 
You can stop completing the survey at any point and choose not to submit it. If you do 
decide to submit the survey, your rights to access, change or move your information are 
limited. This is because we need to manage your information in specific ways in order for 
the research to be reliable and accurate. To safeguard your rights, we will use the minimum 
personally-identifiable information possible. Your data will be anonymous at the point of 
collection. It will therefore not be possible to identify your data in order to withdraw it from 
the study. Please therefore think carefully whether you wish to take part, before completing 
the survey. 
 
You can find out more about how we use your information by contacting the Principle 
Investigator, Dr.Peter Fisher,  
Email: peter.fisher@liverpool.ac.uk   Telephone: 0151 794 4160 
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What if I am unhappy or if there is a problem? 
 
If you are unhappy, or if there is a problem, please contact the Principle Investigator, Dr 
.Peter Fisher: email; peter.fisher@liverpool.ac.uk or telephone: 0151 794 4160 and we will 
try to help. If you remain unhappy or have a complaint which you feel you cannot come to us 
with then you should contact the Research Ethics and Integrity Office at ethics@liv.ac.uk. 
When contacting the Research Ethics and Integrity Office, please provide details of the name 
or description of the study (so that it can be identified), the researcher(s) involved, and the 
details of the complaint you wish to make. 
 
The University strives to maintain the highest standards of rigour in the processing of your 
data. However, if you have any concerns about the way in which the University processes 
your personal data, it is important that you are aware of your right to lodge a complaint with 
the Information Commissioner's Office by calling 0303 123 1113 
 
What if I want to ask questions not included in this information? 
To raise any further questions, please feel free to contact the study Principal Investigator: Dr 
Peter Fisher on (0151-794-4160) / Peter.Fisher@liverpool.ac.uk or the Student Researcher 
Amelia Wright: amelia.wright@liverpool.ac.uk  
Address: University of Liverpool, Whelan Building, Brownlow Hill,     
                     Liverpool, L69 3GB.  
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Emotional Distress and Chronic Fatigue Symptoms 
 
Thank you for agreeing to complete this survey which will take around 20-30 
minutes in total. You may take breaks if you need to. However, we ask that 
you complete the questions within a two-hour time period. 
  
                   Demographics 
 
Please tick appropriate answers: 
 
Diagnosis and Symptoms 
 
I confirm that I have received a clinical diagnosis of Myalgic Encephalomyelitis 
(ME)/ Chronic Fatigue Syndrome (CFS) by a qualified medical professional (e.g. 
GP, ME/CFS Specialist in an NHS CFS Clinic).  
 
 Yes  
 
I have been experiencing chronic fatigue symptoms for 
approximately…….years.                                
 
 
Gender: 
 
 Female     
 Male 
 
Age: ……years 
 
Other illnesses: 
 
I have a clinical diagnosis of Depression 
 
 Yes 
 No 
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I have a clinical diagnosis of Fibromyalgia 
 
 Yes  
 No 
 
 
I have a clinical diagnosis of Chronic Pain Syndrome 
 
 Yes 
 No 
 
 
I have a clinical diagnosis of Irritable Bowel Syndrome. 
 
 Yes 
 No 
 
The Research 
 
How did you hear about this research?  
 
 Through my CFS / ME Clinic 
 Through a CFS / ME support group / online support group 
 Other 
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Appendix M: Hospital Anxiety and Depression Scale 
Please read each item and place a firm tick in the box opposite the reply which comes closest to 
how you have been feeling in the past week. 
Don’t take too long over your replies: your immediate reaction to each item will probably be more 
accurate than a long thought-out response. 
 
Tick only one box in each section 
 
I feel tense or ‘wound up’:    I feel as if I am slowed down:   
 Most of the time ...............................     Nearly all the time .........................   
 A lot of the time ...............................     Very often ......................................   
 Time to time, Occasionally ..............     Sometimes .....................................   
 Not at all ..........................................     Not at all ........................................   
 
 
I still enjoy the things I used to enjoy: 
   I get a sort of frightened feeling like 
‘butterflies’ in the stomach: 
  
 Definitely as much ..........................     Not at all ........................................   
 Not quite so much ...........................     Occasionally ..................................   
 Only a little .....................................     Quite often .....................................   
 Hardly at all ....................................     Very often ......................................   
 
I get a sort of frightened feeling as if 
something awful is about to happen: 
    
I have lost interest in my appearance: 
  
 Very definitely and quite badly .......     Definitely .......................…………   
 Yes, but not too badly ......................     I don’t take so much care as I should   
 A little, but it doesn’t worry me ......     I may not take quite as much care ..   
 Not at all ..........................................     I take just as much care as ever ......   
 
I can laugh and see the funny side of 
things: 
   I feel restless as if I have to be on the 
move: 
  
 As much as I always could ..............     Very much indeed .........................   
 Not quite so much now ....................     Quite a lot ... ..................................   
 Definitely not so much now .............     Not very much ...............................   
 Not at all ...........................................     Not at all ........................................   
 
Worrying thoughts go through my 
mind: 
   I look forward with enjoyment to 
things: 
  
 A great deal of the time ...................     As much as ever I did ....................   
 A lot of the time ..............................     Rather less than I used to ...............   
 From time to time but not too often .     Definitely less than I used to ..........   
 Only occasionally ............................     Hardly at all ....................................   
 
I feel cheerful:    I get sudden feelings of panic:   
 Not at all ..........................................     Very often indeed ..........................   
 Not often .........................................     Quite often ... .................................   
 Sometimes .......................................     Not very often ................................   
 Most of the time ..............................     Not at all ........................................   
 
 
I can sit at ease and feel relaxed: 
   I can enjoy a good book or radio or 
TV programme: 
  
 Definitely ........................................     Often ..............................................   
 Usually ............................................     Sometimes .....................................   
 Not often .........................................     Not often ...................................….   
 Not at all .........................................     Very seldom ...................................   
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Appendix N: Scoring for Hospital Anxiety and Depression Scale  
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Appendix O: Chalder Fatigue Scale  
 
We would like to know more about any problems you have had with feeling tired, weak or lacking in energy 
in the last month.  Please answer ALL the questions by ticking the answer which applies to you most 
closely.  If you have been feeling tired for a long while, then compare yourself to how you felt when you 
were last well.  Please tick only one box per line. 
 
 Less 
than 
usual 
No more 
than usual  
More 
than 
usual  
Much more 
than usual  
 
Do you have problems with tiredness? 
 
    
 
Do you need to rest more? 
 
    
 
Do you feel sleepy or drowsy? 
 
    
 
Do you have problems starting things? 
 
    
 
Do you lack energy? 
 
    
 
Do you have less strength in your muscles? 
 
    
 
Do you feel weak? 
 
    
 
Do you have difficulties concentrating? 
 
    
 
Do you make slips of the tongue when 
speaking? 
 
    
 
Do you find it more difficult to find the right 
word? 
 
    
 Better 
than 
usual 
No worse 
than usual 
Worse 
than 
usual  
Much worse 
than usual  
 
How is your memory? 
 
    
Cella, M. and T. Chalder (2010). "Measuring fatigue in clinical and community settings." J Psychosom Res 
69(1): 17-22 
 
125 
 
125 
 
Appendix P: The metacognitions Questionnaire-30 (MCQ-30) 
 
 
Adrian Wells & Samantha Cartwright-Hatton 
 
This questionnaire is concerned with beliefs people have about their thinking. 
Listed below are a number of beliefs that people have expressed.  Please read each item and say 
how much you generally agree with it by circling the appropriate number. 
Please respond to all items, there are no right or wrong answers. 
 
 
  Do not 
agree 
Agree 
slightly 
Agree 
moderately 
Agree 
very much 
1. Worrying helps me to 
avoid problems in the 
future 
1 2 3 4 
2. My worrying is dangerous 
for me 
1 2 3 4 
3. I think a lot about my 
thoughts 
1 2 3 4 
4. I could make myself sick 
with worrying 
1 2 3 4 
5. I am aware of the way my 
mind works when I am 
thinking through a problem 
1 2 3 4 
6. If I did not control a 
worrying thought, and then 
it happened, it would be 
my fault 
1 2 3 4 
7. I need to worry in order to 
remain organised 
1 2 3 4 
8. I have little confidence in 
my memory for words and 
names 
1 2 3 4 
9. My worrying thoughts 
persist, no matter how I try 
and stop them 
1 2 3 4 
10. Worrying helps me to get 
things sorted out in my 
mind 
1 2 3 4 
11. I cannot ignore my 
worrying thoughts 
1 2 3 4 
12. I monitor my thoughts 1 2 3 4 
13. I should be in control of my 
thoughts all of the time 
1 2 3 4 
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  Do not 
agree 
Agree 
slightly 
Agree 
moderately 
Agree 
very much 
14. My memory can misled me at 
times 
1 2 3 4 
15. My worrying could make me 
go mad 
1 2 3 4 
16. I am constantly aware of my 
thinking 
1 2 3 4 
17. I have a poor memory 1 2 3 4 
18. I pay close attention to the 
way my mind works 
1 2 3 4 
19. Worrying helps me cope 1 2 3 4 
20. Not being able to control my 
thoughts is a sign of 
weakness 
1 2 3 4 
21. When I start worrying, I 
cannot stop 
1 2 3 4 
22. I will be punished for not 
controlling certain thoughts 
1 2 3 4 
23. Worrying helps me to solve 
problems  
1 2 3 4 
24. I have little confidence in my 
memory for places 
1 2 3 4 
25. It is bad to think certain 
thoughts 
1 2 3 4 
26. I do not trust my memory 1 2 3 4 
27. If I could not control my 
thoughts, I would not be able 
to function 
1 2 3 4 
28. I need to worry, in order to 
work well 
1 2 3 4 
29. I have little confidence in my 
memory for actions 
1 2 3 4 
30. I constantly examine my 
thoughts 
1 2 3 4 
 
 
Please ensure that you have responded to all items – Thank You. 
 
 
 
Copyright 1999: Contact A. Wells, University of Manchester, Academic Division of Clinical Psychology. 
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Appendix Q: The Cognitive-Attentional Syndrome 10  (CAS-10) 
 
1. How much time in the last week have you found yourself dwelling on or worrying about problems (e.g. health, 
family, finances)? (Circle a number below) 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
2. How much time in the last week have you found yourself analysing your feelings/symptoms or questioning why 
did this happen to me? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
3. How much time in the last week have you been focusing attention on the things you find  threatening (e.g. 
symptoms, thoughts, bodily checking)?  (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
4. How much time in the last week have you avoided activity or certain situations?  (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
5. How much time in the last week have you tried not to think certain thoughts? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
 
 
 
 
6. How much time in the last week have you used alcohol to cope with thoughts/feelings? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
None of 
the time 
 
 
 
 
    
Half of 
the 
time 
     
All of the 
time 
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7. How much do you believe that worrying or dwelling on thoughts is uncontrollable? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
percent 
certain 
     
Completely 
certain this 
is true 
 
8. How much do you believe that worrying or dwelling on thoughts is harmful? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
percent 
certain 
     
Completely 
certain this 
is true 
 
9. How much do you believe that worrying is helpful? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
percent 
certain 
 
     
Completely 
certain this 
is true 
 
 
10. How much do you believe that anticipating problems will keep you safe? (Circle a number below) 
 
 
0 10 20 30 40 50 60 70 80 90 100 
 
Not at 
all 
 
 
 
 
    
Fifty 
percent 
certain 
     
Completely 
certain this 
is true 
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Appendix R: Participant debrief form 
 
 
 
DEBRIEF FORM 
 
Title Study: Emotional Distress and Chronic Fatigue Symptoms 
 
Thank you for completing the survey.  
The aim of this study is to understand factors which may increase 
emotional distress experienced by people with Chronic Fatigue Symptoms 
(PWCFS). We are interested in whether thought processes (not what people 
think) may increase this emotional distress, regardless of the level of fatigue 
experienced.   
  We hope to be in a better position following this study to develop more 
effective therapeutic interventions for PWCFS who experience emotional 
distress. 
If completing the survey raises any concerns, then there are several options to 
obtain further advice outlined below: 
 
• You could talk to your GP to discuss your concerns. 
 
• There several websites and organizations which provide information and 
advice about CFS / ME. These include: 
 
      Action for ME ( https://www.actionforme.org.uk )  
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4)  The ME Association www.meassociation.org.uk 
5)  
6) In addition, please see the following NHS website for further information 
regarding treatment: 
https://www.nhs.uk/conditions/chronic-fatigue-syndrome-cfs/treatment/   
 
If completing the survey did lead to you feeling any discomfort, you can also 
contact the Principal investigator Dr Peter Fisher, Senior Lecturer in Clinical 
Psychology. Email:  peter.fisher@liverpool.ac.uk 
Telephone: 0151 794 4160 
 
Feedback on the study and the overall results will be available from the Student 
Investigator, Amelia Wright upon request from October 2020.  Please email: 
amelia.wright@liverpool.ac.uk   
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Appendix S:  Distributions and Skewness and Kurtosis Statistics 
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Note: Negative metacognitive beliefs -treated as sked due to shape of distribution curve.  
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Appendix T: Assessment of Regression Assumptions.  
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